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Abstract
Low birthweight and reduced height gain during infancy (stunting) may arise at least in part from adverse early life 
environments that trigger epigenetic reprogramming that may favour survival. We examined differential DNA methylation 
patterns using targeted methyl sequencing of regions regulating gene activity in groups of rural Gambian infants: (a) low and 
high birthweight (DNA from cord blood (n=16 and n=20 respectively), from placental trophoblast tissue (n=21 and n=20 
respectively) and DNA from peripheral blood collected from infants at 12 months of age (n=23 and n=17 respectively)), and, 
(b) the top 10% showing rapid postnatal length gain (high, n=20) and the bottom 10% showing slow postnatal length gain 
(low, n=20) based on z-score change between birth and 12 months of age (LAZ) (DNA from peripheral blood collected from 
infants at 12 months of age). Using BiSeq analysis to identify significant methylation marks, for birthweight, four differentially 
methylated regions (DMRs) were identified in trophoblast DNA, compared to 68 DMRs in cord blood DNA, and 54 DMRs in 
12-month peripheral blood DNA. Twenty-five DMRs were observed to be associated with high and low length for age (LAZ) 
at 12 months. With the exception of five loci (associated with two different genes), there was no overlap between these 
groups of methylation marks. Of the 194 CpG methylation marks contained within DMRs, 106 were located to defined gene 
regulatory elements (promoters, CTCF binding sites, transcription factor binding sites and enhancers), 58 to gene bodies 
(introns or exons) and 30 to intergenic DNA. Distinct methylation patterns associated with birth weight between comparison 
groups were observed in DNA collected at birth (at the end of intrauterine growth window) compared to those established by 
12 months (near the infancy/childhood growth transition). The longitudinal differences in methylation patterns may arise from 
methylation adjustments, changes in cellular composition of blood or both that continue during the critical postnatal growth 
period and in response to early nutritional and infectious environmental exposures with impacts on growth and longer-term 
health outcomes.
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Introduction
About 45% of global deaths in children under 5 years of age are thought to be related to undernutrition (1). Children who 
survive early periods of undernutrition may suffer longer-term consequences, including stunting and other developmental 
deficits (2), which are major contributors to long term morbidity and mortality (3, 4). Although the prevalence of stunting 
declined in sub-Saharan Africa from 42% in 1990 to 32% in 2015, the numbers of affected individuals increased from 47 
million to 58 million (5). Studies estimate that 20% of growth retardation starts in utero where under-nutrition in pregnancy 
increases the risks of intrauterine growth retardation (IUGR) and small for gestation age (SGA) infants, pre-term delivery (6) 
and long-term impaired immunity. It is hypothesized that an adverse early life environment and nutrition induce phenotypic 
adaptations through developmental plasticity (7) to favour survival in the short-term, but at the expense of lifelong effects on 
health (8, 9). 
Nutritional interventions to improve child growth and adult health (10, 11) have had limited success, primarily for the lack of a 
clear understanding of optimal timing, target groups and the composition of supplements. The period of growth and 
development from conception to a child’s second birthday (coined the first 1000 days) is one of the most critical windows of 
opportunity for interventions (12). There is a complex interplay between an individual’s genetic constitution and the 
environment. Responses to extrinsic factors via modifications to the epigenome (which may include to both chromatin 
associated proteins and DNA bases) in the first 1000 days are believed to be important in establishing protective adaptations 
against the impact of under-nutrition and an adverse environment (thrifty phenotype) (13, 14). DNA methylation at CpG 
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A large meta-analysis of multiple epigenome wide association studies (EWAS) by the Childhood Epigenetics Consortium 
found methylation at 914 CpG sites associated with birthweight in whole blood DNA from healthy  neonates, but < 1.3%  
persisted in children (2-13 years), <0.1% in adolescents (16-18 years) and none in adults (30-45 years) (15). The current 
study uses samples and data from a cohort of Gambian mother-infant pairs exhibiting high rates of maternal and child under-
nutrition. Rural Gambian infants are small at birth relative to international standards, show positive growth patterns during the 
first few months of life and then enter a period of reduced growth marked by profound faltering until at least 24 months of 
age (16, 17). Schoenbuchner et al. (16) have suggested that stunting is an extreme adaptation to profound faltering 
episodes potentially arising from a complex interaction of malnutrition, infection and disease. Despite four decades of 
nutrition-sensitive and nutrition-specific interventions halving under-nutrition for young children from rural Gambia, 
substantial (30%) growth faltering remains (17), indicating a gap in our understanding of its complex aetiology.
 Epigenetic studies carried out on Gambian populations have highlighted the importance of maternal nutrition and exposures 
and the effects of maternal nutritional supplementation in this highly seasonal environment. Many aspects of health and 
behaviour in rural Gambia are influenced by the annual seasonality with a single rainy ‘hungry’ season (late June – October) 
followed by a dry ‘harvest’ season (November-May/June) (18, 2). Specifically, there is evidence that seasonal variation in 
nutrition during the periconceptional period influences methylation status in postnatal infants at a number of loci (19), is 
related to methyl-donor nutrient content of the mother’s diet (20, 21, 22, 23) and may be associated with an increase in both 
preterm and SGA infants (18). Periconceptional nutrition supplementation influences methylation changes in cord and 
postnatal infant blood DNA at CpG loci linked to genes associated with infection and immunity (24) and alters methylation at 
imprinted loci (25). Maternal exposure to aflatoxin B1 is also associated with DNA methylation changes at specific loci in 
Gambian infants (26).
The aim of the present study was to identify epigenetic marks that are established during the critical first 1000 days in a 
cohort of rural Gambian infants and explore how these may be associated with normal versus stunted growth outcomes in 
order to determine whether any targets for intervention are associated with pre- and/or post-natal periods of epigenetic 
modification. We used a targeted methyl sequencing approach of genomic DNA from placental trophoblast tissue, cord and 
infant (12 months of age) blood to identify methylation changes. These changes may be useful as biomarkers, highlighting 
genes influenced by exposures during embryonic and foetal development and early infancy, and identifying potential 
pathways through which these may influence growth outcomes at birth and in the first year of life.
Materials and Methods
Samples
The study was conducted among pregnant women and their infants living in the rural West Kiang region of The Gambia. 
Participants were recruited as part of the HERO-G (Hormonal Regulators of Growth) study. The study cohort was 238 
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the samples from individuals used in this study. The full HERO-G protocol is described elsewhere (27). Placentas from 
women who delivered at home were collected by trained field workers and immediately transported on ice to the nearby 
Medical Research Council (MRC) Unit The Gambia Keneba laboratory (within 20-30 minutes) and carefully processed to 
obtain trophoblast material following a standard protocol (see placenta sample collection protocol in supplementary 
materials). Placental samples each of 400mg were taken at four different evenly spaced locations, at least 2cm from the 
edge, and at consistent relative positions in each placenta to mitigate placental tissue heterogeneity. Samples were cut into 
four pieces, placed in RNAlater at a volume of 5 x tissue weight (Cat No 76106, Qiagen) and transported frozen on dry-ice to 
the UK for DNA extraction. After extraction samples from each of the four placental regions were pooled equimolarly. Cord 
blood and infant blood samples were collected into EDTA-lined tubes (BD Vacutainer, pink top) for DNA extraction in the UK. 
Ethical approval for the study was given by the joint Gambia Government/Medical Research Council (MRC) Unit The 
Gambia Ethics Committee (SCC 1313v3), with additional approval from the University of Colorado Institutional Research 
Board (protocol number 13-0441). Community approval was obtained from each participating village, and written, informed 
consent was obtained from each participating family. Samples for analysis were selected retrospectively from the study 
cohort representing (a) the highest 20% and lowest 20% birthweights and (b) according to the top and bottom 10% change 
in length-for-age (LAZ) from birth to 12 months. For the 12 month samples the male average age = 376.4 days, SD 9 days 
(366-409d) and females average age = 378.8 days, SD 10 days (367-413d). Table 2 summarises the number of samples 
analysed after quality testing for each tissue and test group and those that are common between groups. 
Nucleic Acid Extraction 
DNA for DNA methylation studies was extracted from tissues using the Quick-DNA Mini Prep Plus kit (Cat No. D4068, Zymo 
Research). DNA extracted from blood followed the Biological Fluids and Cells protocol and DNA extracted from placenta 
followed the Solid Tissue protocol. DNA abundance and quality were determined after extraction using a Nanodrop ND-1000 
spectrophotometer (Thermo Fisher Scientific, Waltham, Massachusetts, USA). Absorbance ratios (A260/A280 and 
A60/A230) were above the recommended 1.8. DNA from each sample was further quantified on a Qubit® Fluorometer using 
Qubit® dsDNA HS Assay kit (Cat. No. Q32854, Thermo Fisher Scientific, Waltham, Massachusetts, USA). 
Methyl-Seq library preparation
Methyl-Seq was performed using the SureSelect XT Methyl-Seq kit (Cat. No. G9651B, Agilent, Santa Clara, California, USA) 
according to the manufacturer’s protocol (SureSelect XT Methyl-Seq Target Enrichment System for Illumina Multiplexed 
Sequencing protocol, version C.0, January 2015); this covers over 3.7 million individual CpG dinucleotide sequences 
covering CpG islands, CpG island shores, CpG island shelves, under-methylated regions, promoters, enhancers, 
transcription factors, CTCF binding sites, DNase 1 hypersensitive sites and DMRs. Three μg of DNA from each sample was 
initially sheared by Covaris sonication to 150-200bp in size and used to prepare genomic DNA libraries with the SureSelect 
XT Methyl-Seq Library Prep kit. After hybridization with the SureSelect XT Methyl-Seq capture library, targeted regions were 
isolated using complementary RNA baits. Isolated targets were bisulfite converted using the EZ DNA Methylation-GoldTM 
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unaltered. Subsequent PCR amplification creates an unmethylated CGTA transition at unmethylated positions. Each 
sequence-modified, target-enriched library preparation was attached to a readable index (short DNA identifying code) by 
PCR. Libraries were quantified on a Bioanalyzer 2100 (Agilent, Santa Clara, California, USA) using the Agilent High 
Sensitivity DNA kit (Cat. No. 507-4626, Agilent, Santa Clara, California, USA) or using a 2200 TapeStation (Agilent, Santa 
Clara, California, USA) with High Sensitivity DNA ScreenTapes (Cat. No. 5067-5593, Agilent, Santa Clara, California, USA). 
Equimolar indexed libraries were multiplexed (in groups of 6) to a final concentration of 4nM in 20 μL nuclease free dH2O or 
10 mM Tris-Cl, pH 8.5 (Buffer EB, Cat. No. 19086, Qiagen) and run on a single flow cell on an Ilumina NextSeq 500 
according to manufacturer’s instructions using a 2x75bp paired end read kit giving a total read length of 150 (TG NextSeq® 
500 kit High Output Kit v2, Cat. No. TG-160-2002, Illumina). To overcome colour imbalance inherent to low complexity in a 
bisulfite-converted genome, 10% of phiX genome was spiked into the reaction. Q30 scores of bases from NextSeq runs 
were within the threshold recommended by the manufacturer and depth of coverage was approximately 40x.
DNA Data Mapping
FastQC v0.11.4 (28) (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) was used to visualise the sequencing 
quality of the raw reads which were then trimmed using Trim Galore! v0.4.0 (29) 
(http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/). This removes low quality bases (Qscore<20) starting from 
the 3’ end of the read. After trimming, short reads are removed (<20 bases). supplementary figure 1 shows a typical example. 
The Bismark package uses Bowtie 2 alignment software v2.2.6 (30, 31) to align sequences to the reference genome 
(GRCh38/hg19 assemblies) and then methylation data were extracted employing default settings (31). Alignment mapping 
efficiency was in the region of 80% across all samples and is illustrated by supplementary figure 2. The bisulfite error rate, 
estimated from the methylation status at cytosines outside a CpG context was in the region of 1.0% (supplementary figure 3). 
Duplicated reads (removed using Bismark) were in the region of 20%. At each cytosine site, the methylation level was 
calculated as the ratio of the count of “C” (or the number of sequencing reads with methylated cytosine) to the count of “C” 
plus “T” (or the total number of reads covering that site). M-bias plots were generated after methylation data was extracted 
with Bismark to yield the percentage methylation across all reads and to identify any bias (e.g. bias at the end of the read 
due to drop in quality) arising from the position in the read of the cytosine residue being called. supplementary figure 4 
illustrates an example (for infant bloods) of an Mbias plot illustrating the reduction of call quality at the 5’and 3’ends of the 
paired reads. This provides a guide to the extent of necessary sequence trimming (typically 4 bases removed from the 5’and 
1 from the 3’ end). Methylation information was then re-extracted and the output was processed and converted to a 
bedgraph.   
 
Methylation Data Analysis
The resulting bed files from Bismark were used for further statistical analysis. Three comparison groups based on different 
growth criteria were examined: (a) high versus low birthweight babies sampled at birth for placenta and cord blood, (b) high 
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score (LAZ)  between birth and 12 months sampled at 12months for infant blood. Differential methylation between groups 
was examined using BiSeq (31, 32). Only CpGs covered by at least 10 reads were included in the analysis. 
Detection of DMRs
Analysis was performed using R v 3.2.2 (33) and BiSeq version 1.18.0 (32, see review 34). BiSeq is designed specifically for 
targeted bisulfite sequencing data and includes features such as limiting high coverage, removing low coverage, spatial 
correlation, a multiple testing correction, visualization and genomic annotation. DMRs were detected by comparing birth 
weight categories (high v low) or length-for-age (LAZ) scores (high v low) and incorporated sex as a covariate. Briefly, 
sequences were grouped into clusters of adjacent CpG sites. CpG methylation often occurs in clusters and spatial 
correlation is a key characteristic of DNA methylation. As methylation is conserved across short distances, identification of 
these related regions reduces data dimensions and also increases detection power by borrowing nearby CpG information. 
BiSeq CpG clusters were defined as CpG sites covered in at least 25% of samples (defined as frequently covered CpG 
sites) with a maximum distance of 100bp between CpG sites within a cluster and with clusters containing at least 5 of these 
CpGs. To mitigate sequence overrepresentation distorting the data, sequences with greater than 90% of maximum coverage 
were removed. The methylation data was smoothed within CpG clusters using the smoothing algorithm (‘predictMeth’). This 
estimates the true methylation level of each site in each sample. The methylation data were tested for both the test groups 
and resampled datasets under the null hypothesis that differences in methylation are random. The data from both were 
modelled by beta regression, with the group as the independent variable and the methylation probability as the dependent 
variable. A Wald test was used to confirm the parameters used in the beta regression could be included in the model and 
associated p-values were transformed into Z scores to allow DMRs to be detected (31). To account for multiple testing errors 
(multiple testing correction using the Benjamini-Hochberg method - 35), a two-step hierarchical procedure was employed. 
This first tests clusters, then individual CpG sites within those clusters. The two-step approach avoids loss of power by first 
testing at the cluster level and then the CpG in the cluster that showed a change in methylation and hence the number of 
CpGs needing correction is greatly reduced. A variogram was created under the null hypothesis, which estimates the 
correlation in methylation between two CpG sites within a cluster. This was plotted and smoothed, with a sill of 1 for all our 
tests and was combined with the Z scores of the test results of interest to estimate the correlation of Z scores between two 
locations in a cluster. Clusters without differentially methylated CpG sites were removed (FDR >= 0.1), before the remaining 
clusters were trimmed to indicate individual significant CpG sites (FDR <= 0.05). PCA analysis of methylation patterns 
determined from different DNA sequence runs did not reveal any batch effects.
Pyrosequencing
Validation of differentially methylated cytosines as detected by Methyl-Seq was performed by bisulfite pyrosequencing on the 
ZFHX3 gene. Initially, PCR primers were designed using the Pyromark assay design SW 2.0 (Cat. No.9019077, Qiagen, 
USA) and were supplied by Sigma-Aldrich, UK. One of the primers was biotinylated and purified by HPLC. The primers were; 
ZFHX3: forward PCR primer GTTTTAATTTGATTGGGGGGAAAG, reverse PCR primer 
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PCR amplification was performed with 10ng of bisulfite converted DNA using EpiTaq HS (Cat. No. R110A, TaKaRa Bio Inc, 
Japan).  PCR was set up according to the manufacturers’ instructions but the concentration of MgCl2 varied between 15-
25mM dependant on the primer set. Both methylated and unmethylated controls from the EpiTect PCR control DNA kit (Cat. 
No. 59695, Qiagen, USA) were run alongside. Thermal cycling conditions were performed using a touchdown programme 
with an annealing temperature range of 53°C - 62°C and cycle number range of 25-35, dependant on primer set. The PCR 
products were electrophoresed on a 3% agarose gel to check for product specificity. Pyrosequencing was then performed on 
the PyroMark Q24 Vacuum Workstation (Qiagen, USA) as described in the manufacturer’s instructions. PyroMark CpG 
software Design 2.0 (Cat. No. 9019067, Qiagen, USA) was used in this assay and primers with the best quality score were 
selected. Bisulfite conversion was shown to be efficient for all samples as the fluorescence signal by cytosine in a non-CpG 
context was ≤ 1% of the signal produced by thymine.
Cellular Heterogeneity Assessment Between Sample Groups
For cord blood, cell composition was compared between low and high birthweight groups using overlaps with a cord blood 
cell type specific reference panel of 215,000 CpGs derived from the Illumina EPIC 850k array (ref: 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6284779/). The reference panel set of CpG loci was used to find overlaps 
with the processed MethylSeq capture dataset. Co-methylation patterns extend up to several hundred base pairs across 
CpG clusters (36, 37). In order to obtain enough coverage for the regions covered by the EPIC reference set, we used 
intervals of 200 bases centred around the locations of the EPIC reference CpG set (updated in Human Genome - HG19). 
This yielded 14993 regions each containing CpG loci as present in the processed methyl capture sequence data set. 
Methylation calls were extracted from the processed sequence data as described above and the mean values in these 
regions were used to generate PCA plots and heatmaps to calculate the correlation values between experimental groups 
(using Pearson correlation). In the absence of a 12 month blood reference panel, the adult blood  reference panel based on 
the Illumina Infinium HM450k and EPIC 850K methylation chips (38, 39) was used and processed in the same way for 
coverage across the Methylseq capture dataset. An interval of 200 bases yielded 33 regions each containing CpG loci 
(providing coverage for CD4 and CD8 lymphocytes, NK cells, neutrophils, B-cells and monocytes) that are present in the 
processed methyl capture sequence dataset to compare the 12 month groups.
CpG and Gene Annotation
Ensembl was used to annotate differentially methylated CpGs (based on hg38 version GRCh38 human genome build) to 
determine their location with respect to regulatory features. Ontologies, mutational and functional data of those genes 
associated with significant differentially methylated CpGs were determined by using the U.S. National Center for 
Biotechnology Information (NCBI; Bethesda, MD, USA; http://www.ncbi.nlm.nih.gov/) Gene, Online Mendelian Inheritance in 
Man (OMIM), PubMed databases and the Database for Annotation, Visualization and Integrated Discovery v6.7 (DAVID - 
http://david.abcc.ncifcrf.gov/) (40). Disease associations were determined by interrogating the Genetic Association Database 
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to provide an overview of gene ontology (GO Terms) defining protein classes, cellular components, biological procesess and 
molecular functions of genes implicated by methylation marks.
Results
Quality Triage of Sample Cohorts
All samples underwent assessment to exclude maternal contamination and poor-quality samples. Maternal blood 
contamination of cord blood (for both sexes) was assessed using marker CpGs that are only methylated in adult blood DNA, 
and maternal contamination of placenta trophoblast samples from males was also flagged by examining the levels of Y DNA 
methylation dilution (43); see supplmentary figure 5a and b Poor quality and/or obvious outlier samples were identified by 
plotting a heatmap of the methylation data for each experimental group (see example of the methylation data from the 
birthweight cohort at 12 months of age in supplementary figure 6). The major component of variation was sex. Principal 
Component Analysis (PCA - done with and without inclusion of the sex chromosomes) matrices were also applied to a list of 
available variable information for the subjects contributing to each cohort and tissue sample (see supplementary table 1) to 
determine whether they had a significant effect on the variation  in the data. Examples for sex (male/female), birthweight 
category (high/low) and season (dry/wet) are illustrated in supplementary figures 7a, b and c; only sex contributed 
significantly to variation in the data. Sample sets emerging from these analyses were re-analysed with sex as a covariate.
Assessment of Confounding Cellular Heterogeneity
There is no available cell type specific reference set for cord and adult blood to assess cell composition changes based on 
DMRs detected by Methyl-Seq data. Potentially confounding differences in cell-type composition between cord blood 
groupings (high and low birthweight) and infant blood groupings (high and low birthweight and length for age) were, therefore, 
assessed by using DMR regions within the capture DNA sequence data set that overlap within a 200 base-pair interval with 
the EPIC 850k cord blood and Infinium HM450k adult blood cell type specific CpG panels (see methods). The adult overlaps 
were used for the 12 month infant blood data in the absence of an age-related reference panel for this time point. The 
heatmap and PCA plots are shown in supplementary figures 8 and 9. For both cord and infant blood data, the heatmaps 
indicate high correlation between samples and no clear clustering according to comparison groups. PCA analysis indicates 
inter-individual differences in cellular composition. For the small number of probes from the adult blood reference panel 
present within the Methyl-Seq capture DNA sequence dataset, the analysis shows separation of individual samples into two 
groups; this may reflect the small number of probes available and their disproportionate weighting or variation in the rate of 
loss of nucleated erythrocytes between individuals. However, in all three PCA plots the variation between samples captured 
in PC1 and PC2 is distributed fairly uniformly across both experimental groups (high or low birthweight or tall or short height 
for age) indicating little difference in cellular composition between comparison groups to confound the determination of 
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Differentially Methylated Loci Identified Through BiSeq Analysis
The total number of significant differentially methylated regions (DMRs) and the direction of median methylation change 
identified for each comparison group (placenta- birthweight, cord blood-birthweight, infant blood-birthweight at 12 months 
and infant blood-LAZ) by BiSeq analysis and the total number of significant CpGs they contain is shown in supplementary 
table 2a-d and summarized in table 3; 194 CpG loci in total.  Each significantly differentially methylated CpG in each DMR 
was examined for the presence of single nucleotide polymorphism (SNP) directly in the CpG; these are shown in 
Supplementary table 2a-d. Apart from 3 SNP-containing CpGs, all the MAFs (minor allele frequencies) were <0.01. For the 
CpGs associated with implicated genes RPS6KA2, PRSS3 and GAR1, the MAFs were <0.03, <0.11 and <0.02 respectively. 
These MAFs are at a level that would not significantly alter the estimation of methylation differences between test groups.. 
The distribution of CpGs between gene regulatory elements, gene bodies and intergenic regions is shown in table 4 (see 
supplementary tables 2a-d for full details on all DMRs and CpG locations). Figure  1 a-d provides an overview of the gene 
ontology (determined using PANTHER v14.0  available at http://www.pantherdb.org) characterizing genes implicated by 
differential methylation marks. The pie charts sumarise the distribution of this gene set across GO terms defining molecular 
functions, biological processes, cellular components and protein classes. It can be seen that certain GO categories 
predominate. For example, analysis of molecular function reveals that binding, catalytic activity, molecular function regulator 
and transcriptional regulator activity are most prominent. Detailed information on the genes and proteins in each of the GO 
categories can be obtained by uploading the gene lists to http://www.pantherdb.org from supplementary table 2a-b and 
interrogating each pie chart sector. 
Very few of the differentially methylated CpGs found in DMRs identified from the cord blood comparisons are found in the 12 
month infant blood comparisons; (a) of the four closely linked CpGs associated with TNXB, one (upstream intergenic) is 
differentially methylated in the cord blood birthweight group and the remaining three (within intron 1 of the gene) in the 12 
month infant blood birthweight group and (b) the intergenic CpG upstream of the HLX gene is differentially methylated in 
both the 12-month birthweight and 12-month length for age groups.
CpG Loci Showing 5% or Greater Methylation Change
We have chosen to focus on those marks that show 5% or greater methylation change. Figure 2  summarises the CpGs that 
have been located to regulatory features (promoters, CTCF binding sites, transcription factor binding sites – 56 CpG loci in 
total) and table 6 those located to gene bodies (introns and exons) and closely linked intergenic regions (64 CpG loci in total). 
Figures 2 and 3 also present the locations of CpGs (based on hg38 release 85 from ENSEBL) with respect to the 
Transcription Start Site (TSS) of genes implicated by location (93 in total), the median p-value for the DMR corrected for 
multiple testing, direction and change in median methylation value, GWAS disease associations and a short vignette 
summarizing any mutational data and functional studies of implicated genes culled from the various databases outlined in 
the materials and methods. Finally, figures 2 and 3 flag whether any of the DMR associated genes are also subject to Trans 
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(variation of methylation that influences expression of an adjacent gene) collated in the Bios QTLBrowser held at 
www.genenetwork.nl/biosqtlbrowser (85, these are marked in red in the first column). This data was based on the analysis of 
cohorts from the Dutch population and may only partially reflect genetic variation in the Gambian population with Trans or 
Cis-eQTL effects.
The implicated gene names in figures 2 and 3 are colour coded according to categories of gene function/disease revealed by 
functional and/or mutation analysis (see legends) and figure 4 summarises the numbers of implicated genes found in 
associated disease categories bearing the same colour coding. It is immediately clear that neurological, growth and 
development and oncological disorders are the most prominent amongst the implicated genes showing 5% or greater 
methylation change.
Replication of Findings in Other Methylation Studies
Identification of a significant proportion of the same implicated genes reported in related studies provides strong validation of 
the findings reported here. Highlighted in red bold in supplementary table 2a-d are the DMR-implicated genes that are also 
documented in the recent large meta-analysis of multiple EWAS by the Childhood Epigenetics Consortium examining DNA 
methylation associated with birthweight (15). When all genes (4848, representing about 19% of the estimated 25,000 genes 
in the human genome) from the consortium study associated with 8170 CpGs significant after FDR correction for multiple 
testing are screened, 62 DMR implicated genes from the current study show a match (of which 34 show >5% methylation 
change). If this is restricted to those genes (729; about 2.9% of human genes) associated with 914 CpG loci surviving 
Bonferroni correction (p<1.06E-7), then 11 matches are found (marked with a red asterisk of which 10 show >5% 
methylation change in the current study). The vast majority of CpGs in the meta-analysis are located within or closely linked 
to genes. Thus taking the number of genes in the genome as 25,000, the approximate probability of a match by chance for 
any given DMR-implicated gene in the present study is 0.19 (4848/25000) for all genes and 0.029 (729/25000) for those 
associated with the 914 CpG loci. The probability that these matches have occurred by chance for 62 and 11 genes is 0.19-
62 and 0.029-11 respectively. 
Comparisons have been made to two further studies examining the impact of gestational age (86, where some of the data is 
subsumed in the large meta-analysis mentioned above) and smoking on birthweight (87); these share, respectively, 53 
(marked with a green asterisk in supplementary table 2a-d) and 11 (marked with a blue asterisk) genes associated with 
differential methylation identified in the current study. These two studies identify a further 22 DMR associated genes that 
overlap with our findings, bringing the replication in other related studies to 84 (48%) of the 173 implicated genes we have 
documented (The asterisks in tables 5 and 6 mark which of those shared genes show 5% or greater methylation change – in 
total 49 of the 93 in tables 5 and 6  between the three birthweight-related studies).
The genes ZNF678, VTRNA2-1, SCRIB and TNXB match those reported in other studies on maternal exposures and 
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supplementary table 2a-d) and SEMA3B, ARID1B and HOXA10 from the Cambridge Baby Growth Study (88 – marked with 
black double asterisks).
The high degree of replication observed in related studies provides robust validation of the findings reported here. 
Pyrosequencing analysis of the methylation mark associated with the ZFHX3 gene was performed to illustrate an example 
experimental confirmation of methylseq derived methylation data. Table 5 summarises the data for several individuals 
selected from the high and low groups for the 12 month LAZ comparison. The results in table 5 show good concordance 
between the two methods in both the quantum and direction of change when compared to the median methylation value 
change derived from the group comparisons by Biseq analysis of methylseq data.
Discussion
It has been suggested that epigenetic changes may be involved in the mechanism of reprogramming induced by under-
nutrition, infection and adverse environmental exposures, although, it is not clear whether these are primary or secondary 
events in the chain of causality. This paper has used extremes of variation in birth weight and subsequent gains in length to 
examine associated methylation changes in DNA from trophoblast and cord blood DNA from small and large babies, and 
blood DNA from 12 month old infants analysed both according to their size at birth and their change in length from birth to 12 
months (LAZ). 
The methylation marks found at birth and those at 12 months in relation to birthweight show little longitudinal persistence 
(see tables 5 and 6 and supplementary table 2a-d). This suggests ongoing epigenetic adjustments, significant changes in 
blood cellular composition (such as the loss of nucleated erythrocytes – 89) or both in the critical postnatal growth period and 
the subsequent infancy-childhood growth transition (ICT) (90). Nonetheless, what does persist at 12 months is different, 
almost completely non-overlapping methylation patterns (not confounded by cellular composition differences) between the 
high and low birthweight comparison groups and the comparison groups showing rapid or slow post-natal height gain. These 
two distinct methylation patterns may reflect different interactions with nutritional, infectious and other environmental 
exposures during the post-natal growth phase potentially associated with negative or positive growth trajectories or a 
combination of both. Thus, any continued challenges (such as those provoked by under nutrition and infection) to 
homeostasis during the development period may trigger epigenetic programming and shift the timing and duration of these 
periods of growth. The study reported by Bernstein et al. (91) has revealed an accelerated transition to a childhood pattern of 
growth in Gambian compared to UK infants. A later transition, observed in UK infants, extends the high growth rate 
experienced during the infancy stage. This is reduced in Gambian infants, potentially impacting on growth outcomes in 
childhood while diverting energy into other processes critical for responses to acute infectious challenges; later 
developmental stages in this population offer an extended window for catch-up growth.
Over half (54.3%) of the identified methylation marks are located in gene regulatory elements, 30.3% in gene bodies and the 
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implicated genes may occur by impacting the functionality of cis transcriptional regulatory elements or changing chromatin 
conformation and accessibility to the transcriptional machinery. Several of the methylation marks are found in the binding 
site (an estimated 326,000 in the human genome) for the multifunctional CTCF zinc finger protein. This protein plays a key 
regulatory role through a number of varied functions that include influencing chromatin architecture (binding at chromatin 
domain boundaries and the formation of chromatin loops), binding to promoters, enhancers and within gene bodies and 
recruitment of transcription factors. The protein can also act as an insulator, blocking long-range promoter-enhancer 
interactions (for review see 92). Of particular relevance is the observation that methylation at CTCF binding sites in imprinted 
regions can disrupt the binding of the CTCF protein and its insulator activity (93) and, more generally, at many other 
methylated sites outside imprinted regions (94). From the annotation associated with each of the CpG loci covered by this 
methyl-seq capture set, almost all the methylation marks described in this study are in regions containing DNAse 1 
hypersensitive Sites (DHS –markers of  DNA regulatory regions and transcriptionally active open chromatin) described by 
the ENCODE (Encyclopedia of DNA Elements - 95) project. The ENCODE project has shown that a small proportion (~ 5%) 
of DHSs are found in TSS (Transcirption Start Site) regions, that most are located in introns and intergenic DNA and that 
there is cell type specificity in the distribution of DHSs. This indicates that the majority of methylation marks reported in our 
study are potentially in areas of remodelled open chromatin associated with transcriptional activity and may influence target 
gene activity possibly by altering chromatin architecture. Tables 5 and 6 also indicate that a number of the DMR-associated 
genes showing 5% or greater methylation change are subject to trans and/or cis genetic variation (Trans-meQTL and Cis-
meQTL) that impacts the level of methylation of closely linked CpG loci; in some cases these methylation changes affect 
gene expression (Cis-eQTM). One consequence of this polymorphism in the genetic modulation of methylation marks is that 
it is likely to lead to a diversity of methylation responses to environmental exposures in different populations. Thus interaction 
between environmental exposures, genetic background and modulation of methylation patterns will have to be assessed for 
each study population.  
Distribution of implicated genes across GO term categories demonstrates that they encompass biochemical and biological 
functions that include signalling or interaction with signalling pathways; interacting with or acting as receptors; constituents of 
or interacting with the extracellular matrix; deposition of connective tissue; structure and function of the actin cytoskeleton; 
trafficking across cellular membranes; cell cycle control and cellular growth; transcription regulation; metabolic regulation 
(see figure 1). Biological functions revealed by functional studies, animal models and mutation analysis primarily highlight 
roles in neurological, growth and developmental, neoplastic and immunological dysfunction (see figures 5, 6 and 7and 
supplementary table 2a-d for details). The precise impact of the methylation changes on the expression of implicated genes, 
however, is unknown and awaits more detailed functional analysis. Nevertheless, the location of these methylation marks 
within appropriately positioned regulatory elements and gene bodies or in close intergenic linkage to implicated genes, 
encourages their consideration as biomarkers associated with and the genetic pathways within which they are active in as 
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In total, eighty-four genes implicated by DMRs (shown in red bold and flagged by green and blue asterisks- see 
supplementary table 2a-d) are shared with DMR associated genes reported in the large array-based meta-analysis of 
multiple EWAS by the Childhood Epigenetics Consortium and two further related studies (15,86,87). This demonstrates 
concordance with a substantial proportion (48%) of the genes documented in the current study and provides robust 
validation of the Biseq analysis of methylseq data. Eleven matched genes are associated with CpG loci surviving stringent 
Bonferroni correction in the Kuppers et al. study (15) (marked with a red asterisk in supplementary table 2a-d). Differences in 
genetic background, environmental exposures and nutrition between populations contributing to different studies could lead 
to methylation changes at different CpG loci but still affect DMRs associated with the same implicated genes. In the case of 
MAD1L1 and NFIX, differential methylation has been detected at the same Bonferroni significant CpG sites that are reported 
in the meta-analysis 15). MAD1L1 (a component of the mitotic spindle-assembly checkpoint) has a role in cell cycle control 
and tumour suppression and methylation levels have been strongly correlated with hepatocellular carcinoma (96). It is also a 
susceptibility gene for bipolar disorder and schizophrenia with a risk allele linked to reward systems in healthy adults (97). 
NFIX is most highly expressed in brain, fat and prostate, is linked to cancer (DNA hypermethylation associated with lung 
adenocarcinoma - LUAD) (98), muscle development and dystrophies (99). Interestingly, 19p13 microduplications 
encompassing NFIX are responsible for intellectual disability, short stature and small head circumference (100). 
Three implicated genes match those flagged by methylation changes found in DNA from babies in the Cambridge Baby 
Growth Study investigating the effects of maternal gestational diabetes or intrauterine growth retardation (88). ARID1B and 
SEMA3B are potential tumour suppressor genes. ARID1B is a chromatin remodelling factor and individuals with ARID1B-
related disorder have many phenotypic features including slow growth (101). The third gene is HOXA10 (homeobox A10), 
whose expression is down regulated in endometriosis but in late gestation is required for proper placental differentiation and 
function (100). 
Implicated genes ZNF678 (a zinc finger gene), VTRNA2-1, SCRIB and TNXB have been reported in other Gambian-based 
studies investigating periconceptional nutritional exposures associated with differential methylation (11, 22, 26). VTRNA2a-1 
is a non-coding RNA gene that functions as a tumour suppressor (47, 48, 49, 50) and is an imprinted locus (51, 52). SCRIB 
(a scaffold protein found at epithelial adherens junctions and neuronal presynaptic compartments) can act as a tumour 
suppressor gene and has been shown to be mutated in severe neural tube defects (see OMIM entry 607733). TNXB is an 
extracellular matrix glycoprotein thought to function in matrix maturation during wound healing. Different pathogenic alleles 
give rise to Ehlers-Danlos Syndrome (64) and a form of chronic kidney failure, Vesicoureteral Reflux –VUR (65), both of 
which involve alterations to collagen deposition in the extracellular matrix.
The genes DLK1 and MEG9 (LINC00584 - long intergenic non-coding RNA) are worthy of further comment given their 
location within an important imprinted region on chromosome 14 at 14q32. As revealed by maternal and paternal Uniparental 
Disomy (UPDm and UDPp, respectively) and genetic and functional studies of individual genes encompassed within the 
locus (for review see OMIM entries 601038, 60563, 611896, 172690, 613648 and ref 103), the region has a major impact on 
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coding snoRNAs (small nucleolar organiser RNA), miRNAs (microRNAs), LncRNAs (long non-coding RNAs) and LINC 
RNAs under the control of an intergenic differentially methylated region (IG-DMR) (104). Three genes (DLK1, RTL1 and 
DIO3) are all expressed from paternal alleles. DLK1, containing six epidermal growth factor repeats, has reduced plasma 
levels in women bearing small for gestational age babies (105),  is an inhibitor of adipocyte differentiation (106) and shows 
genetic association with age of menarche (107, 108, 107, 110). RTL1 is essential for maintenance of foetal capillaries and 
potentially involved in formation of the chorioallantoic placenta (111), while DIO3 (Thyoroxine Deiodinase Type III) is 
essential for the maturation and function of the thyoroid axis (112). A further four genes (MEG3, RTL1as, MEG8 and MEG9) 
are all expressed from maternal alleles. MEG3 is a LncRNA affecting growth and development in Meg3 knock-out mice 
(113); RTL1as is an anti-sense transcript to the paternally expressed gene RTL1 and encodes a number of microRNAs that 
may regulate the expression of RTL1 (105); MEG8 is a LncRNA involved in the regulation of trophoblast proliferation and 
invasion, and implicated in spontaneous early abortion (114) and MEG9, a LINC RNA involved in megakaryocyte 
differentiation and angiogenesis (70) shows genetic association with body mass index and age of menarche (107). 
The UPDm (no paternal transcripts: Temple Syndrome) phenotype is characterised by pre-and postnatal growth retardation, 
neonatal hypotonia, precocious puberty and facial dysmorphism. The UPDp (no maternal transcripts: Kagami-Ogata 
Syndrome) phenotype is characterised by severe growth retardation, skeletal abnormalities, facial anomalies and abdominal 
muscular defects. Trans-regulation by maternally expressed small non-coding RNAs from the 14q32 region on the activity of 
other genes in the genome is likely to contribute to these complex phenotypes (105). On the maternal chromosome DLK1 is 
silenced. The current study shows a 6% methylation difference of a DLK1 DMR (higher in high birthweight than low 
birthweight babies). In contrast, MEG9 is silenced on the paternal chromosome and shows a 22% methylation difference of a 
MEG9 DMR (higher in high birthweight than in low birthweight babies). It is not clear what the impact of these methylation 
marks is on expression levels as they lie outside the immediate promoter within the gene body. Nevertheless, given that both 
methylation marks are in DMRs containing DHSs marking potentially open chromatin, it is reasonable to suggest that 
alteration of the methylation landscape in this region of chromosome 14 could impact chromatin architecture and gene 
activity with a bearing on growth and development outcomes. It is interesting to note that a study examining the effect of 
maternal periconceptional micronutrient supplementation of Gambian mothers found increased methylation of a DLK1 
associated CpG in cord blood DNA from offspring of mothers who had received the supplements (24).
A number of limitations should be noted. An accessible tissue such as blood as a proxy for methylation changes in other key 
target tissues will not capture all the relevant alterations in methylation status. However, there is sufficient concordance 
between tissues to yield a subset of potentially relevant loci (115, 116, 117). Analysis has been performed with males and 
females combined; hence sex differences in the methylation patterns have not been determined. The sample size is small, 
nevertheless, as outlined in the methods, BiSeq is designed for the analysis of targeted methyl sequence data and takes 
advantage of the conservation of methylation across short distances, co-assessing methylation changes at several individual 
cytosine residues within intervals of 100 base pairs. This reduces data dimensions and increases detection power by 
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status across any given genomic region; this has allowed identification of statistically valid differentially methylated CpGs 
from this small study. Greater coverage (3.7 million CpGs as compared to the Illumina HM450k and Epic 850k chips) of the 
SureSelect targeted sequencing approach of key gene regulatory elements (adjacent and distant, proximal or distal) to 
genes they control, offers the opportunity to identify additional methylation marks not necessarily scored by the array-based 
platforms.
Studies such as the one reported here provide associations and not cause and effect relationships between genes and 
phenotypes. Mutational evidence is helpful in establishing the likelihood that a gene contributes to a complex phenotype. 
Identification of methylation marks can be useful in that (a) they might act as biomarkers of early life adverse exposures that 
impact on early growth and may potentially indicate those individuals with higher future disease risks and (b) potentially flag 
genes that may be useful intervention targets to ameliorate the consequences of stunting. An integrated large scale analysis 
of inter-individual variation of methylation marks in relation to genotype (Trans and Cis-meQTLs), eQTLs (expression 
quantitative trait loci including Cis-eQTMs), disease susceptibility, developmental phenotypes, nutrition and environmental 
exposures provides a means of potentially unpicking causal relationships and the relevance of implicated genes. Clearly, the 
most effective approach to mitigate stunting and associated disease susceptibilities would be to ensure healthy nutrition, 
adequate sanitation and living conditions early in the life course.
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Panther version 14 was used to provide an overview of the gene ontology characterising genes implicated by methylation 
marks. Panther 14.0 identified 161 hits from the uploaded list of 173 genes. A. GO terms for Molecular Function found 93 
molecular function hits. B. GO terms for Biological Process found 276 process hits. C.GO terms for Protein Class found 94 
class hits. D. GO terms for Cellular Component found 300 cellular component hits. Colour coding has been assigned starting 
at 12 o’clock and working clockwise on the pie chart.
Figure 2   Implicated Genes Associated with Methylation Changes of 5% or Greater in Regulatory Elements
This figure documents those genes where a methylation change of 5% or greater has occurred within a defined regulatory 
feature. It also provides a summary of function and any disease associations resulting from Genome-Wide Association 
Studies (GWAS – culled from the GAD and EMBL genetic association catalogue databases), mutation analysis and 
functional investigations. The methylation change is expressed relative to the high birthweight and high length for age groups. 
All mapping of DMRs is based on human genome build hg38 version GRCh38 of the human genome. The positions of CpGs 
is given in relation to the Transcription Start Site (TSS) of the implicated gene. Also shown highlighted in red in the first 
column is whether the gene is associated with Trans and/or Cis-meQTLs and/or Cis-eQTMs. Where plural is shown, this 
indicates 2 or more Trans-meQTLs,Cis-metQTLs or Cis-eQTMs associated with the gene (information obtained from the 
BIOS QTL Browser at www.genenetwork.nl/biosqtlbrowser). NI= No Information. Colour key of gene disease and functional 
associations: brown=neurological; purple=fertility; light blue=growth and development; dark blue=oncological; light 
green=immunological. The asterisks mark the implicated genes found associated with methylation marks in related studies 
(15, 86, 87).
Figure 3  Implicated Genes Associated with Methylation Changes of 5% or Greater in Gene Bodies and Intergenic 
Regions
 
This figure documents those genes where a methylation change of 5% or greater has occurred within a gene body or 
intergenic region. It also provides a summary of function and any disease associations resulting from Genome-Wide 
Association Studies (GWAS – culled from the GAD and EMBL genetic association catalogue databases), mutation analysis 
and functional investigations. The methylation change is expressed relative to the high birthweight and high length for age 
groups. All mapping of DMRs is based on human genome build hg38 version GRCh38 of the human genome. The positions 
of CpGs is given in relation to the Transcription Start Site (TSS) of the implicated gene. Also shown highlighted in red in the 
first column is whether the gene is associated with Trans and/or Cis-meQTLs and/or Cis-eQTMs. Where plural is shown, this 
indicates 2 or more Trans-meQTLs,Cis-metQTLs or Cis-eQTMs associated with the gene (information obtained from the 
BIOS QTL Browser at www.genenetwork.nl/biosqtlbrowser). NI= No Information. Colour key of gene disease and functional 
associations: brown=neurological; purple=fertility; light blue=growth and development; dark blue=oncological; light 
green=immunological; dark green=connective tissue; orange= metabolic; vermillion=cardiovascular; grey=hearing.  The 
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Figure 4   Number of Implicated Genes from Figures 2 and 3 Associated with Different Disease Categories
The colour key allows cross-reference to the gene lists in figure 2 and 3. Neur=Neuorlogical; Repro=Reproductive; Growth 
and Dev=Growth and Development; Onco=Oncological; Imm=Immunological; Conn Tiss=Connective Tissue; Cardio-
vasc=Cardi-vascular
Legends to Tables
Table 1 Summary of Individual Specific Data of Those Included in the Study
Summary of individual specific data for subjects contributing to study. Key: Mat Age = Maternal age, GA = Gestational age, 
S_MOC = Season of month of conception, S_MOB = Season of month of birth, BW = Birthweight, LAZ = Length for age Z 
score change birth to 12 months, BL = Birth length, D = Dry season, W = Wet season, pl = Placenta, CB = Cord blood, 12mB 
= 12 month blood sample selected on birthweight, 12mH = 12 month blood sample selected on LAZ score. The samples 
categorized as high or low for both birthweight and length for age were those used in the analysis. Table 2 shows the 
numbers and sex for each tissue.
Table 2  Summary of DNA Samples Analysed in the Study  
Numbers of DNA samples analysed for each tissue according to sex and test group and the number of
of subjects in common between tissues and test groups. Key: BW = Birthweight, LAZ = Length for age Z score.
Table 3  Summary of Numbers of DMRs, CpG Loci and Implicated Genes 
Summary of total number of DMRs, CpG loci, implicated genes (in brackets) and direction of median methylation change 
identified from the comparisons made at each time-point between groupings. Key: BW = Birthweight, LAZ = Length for age Z 
score. Median methylation change is expressed relative to the high birthweight and high length for age groupings.
Table 4  The distribution of methylation marks between regulatory features, gene bodies and intergenic regions.
Table 5  Methylation Analysis of the DMR Associated with the ZFHX3 Gene by Pyrosequencing 
This table compares the methylation levels determine for the DMR associated with the ZFHX3 gene by pyrosequencing and 
methylseq analysis. Individuals from the high (n=5) and low (n=6) 12 month length for age comparison groups were selected 
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quantum and direction of change is close to that observed for median methylation change from the comparison of the high 
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Table 1 
 

















MALES            
 20.27 36 Primiparous W W 1.7 low 45.00 -0.45 low Pl, CB, 12mB, 12mH 
 35.19 38.1 Multiparous D D 2.14 low 44.43 1.55 high Pl, 12mB, 12mH, 
 33.32 38.1 Multiparous D D 2.32 low 47.00 0.53 mid Pl, CB, 12mB 
 38.61 38.6 Multiparous W D 2.38 low 45.50 -0.39 low Pl, CB, 12mB, 12mH 
 23.6 37 Primiparous W D 2.44 low 47.80 0.42 mid Pl, CB, 12mB 
 23.32 37.8 Multiparous W D 2.48 low 45.90 0 mid Pl 
 26.33 40.7 Multiparous D D 2.51 low 49.00 2.14 high CB,12mB, 12mH 
 27 39.9 Multiparous W W 2.53 low 49.00 1.7 high Pl, CB, 12mB, 12mH 
 24.39 38.9 Multiparous D D 2.56 low 47.40 0.99 high Pl, CB, 12mB 
 18.65 39.4 Primiparous D W 2.59 low 50.40 0.5 mid Pl, CB, 12mB 
 31.49 41.2 Multiparous W D 2.59 low 42.30 -0.49 low Pl, 12mB, 12mH 
 20.67 38.9 Primiparous D D 2.67 low 46.70 1.8 high 12mB, 12mH 
 31.16 40.7 Multiparous D D 2.7 low 48.40 1.21 high 12mB, 12mH 
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 38.5 41 Multiparous D W 2.92 mid 49.00 -0.91 low 12mH 
 40.82 39.7 Multiparous D W 2.96 mid 50.10 1.96 high 12mH 
 28.69 40.7 Multiparous D D 3.06 mid 49.33 -0.43 low 12mH 
 41.27 40.7 Multiparous D D 3.07 mid 52.00 -0.75 low 12mH 
 32.82 39.9 Multiparous W D 3.13 mid 53.00 -0.66 low 12mH 
 27.11 41.2 Multiparous D D 3.26 high 51.50 -0.49 low 12mH 
 23.04 39.4 Multiparous W D 3.26 high 51.23 -0.91 low 12mH 
 29.15 38.6 Multiparous D D 3.26 high 48.00 1.52 high 12mB, 12mH 
 37 38.1 Multiparous D D 3.27 high 48.10 1.37 high 12mB, 12mH 
 37.53 38.1 Multiparous W D 3.28 high 49.30 1.08 high Pl, CB, 12mB, 12mH 
 25.64 40.2 Multiparous D W 3.34 high 51.00 0.95 mid Pl, CB, 12mB 
 34.46 40.4 Multiparous W W 3.34 high 48.30 0.19 mid Pl, CB, 12mB 
 20.29 40.2 Multiparous W W 3.36 high 53.47 -1.01 low Pl, CB, 12mB, 12mH 
 37.18 39.1 Multiparous D D 3.36 high 50.50 1.82 high Pl, CB, 12mB, 12mH 
 22.07 41 Multiparous D W 3.37 high 48.47 0 mid Pl, CB 
 28.91 40.2 Multiparous D D 3.39 high 50.50 0 mid Pl, CB 
 23.51 38.9 Multiparous D W 3.45 high 50.47 1.02 high Pl 
 31.48 40.7 Multiparous D D 3.5 high 50.00 0.08 mid 12mB 
 37.96 41.2 Multiparous D D 3.52 high 50.40 1.7 high 12mB, 12mH 
 40.36 39.1 Multiparous W D 3.55 high 49.50 0.6 mid Pl 
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 39.33 40.7 Multiparous D D 3.72 high 52.50 -0.93 low Pl, CB 
 31.19 41.8 Multiparous D D 3.79 high 50.77 -0.28 mid Pl, CB, 12mB 
 39.69 40.2 Multiparous D W 3.8 high 53.00 -1.35 low Pl, CB, 12mB, 12mH 
 39.65 41 Multiparous D W 3.9 high 50.00 0.82 mid Pl, CB, 12mB 
 36.61  Multiparous D W    1.31 high 12mH 
FEMALES            
 18.72 39.4 Primiparous D W 2.42 low 46.00 1.12 high Pl, 12mB, 12mH, 
 19.04 39.9 Primiparous W W 2.46 low 46.00 0.34 mid Pl, CB, 12mB 
 29.89 39.1 Multiparous D D 2.48 low 50.00 0.54 mid Pl, CB 
 21.16 38.9 Multiparous D D 2.48 low 45.50 1.86 high 12mB, 12mH 
 23.01 38.7 Multiparous D D 2.5 low 47.00 0.11 mid 12mB 
 39.72 38.6 Multiparous D W 2.53 low 46.40 -0.28 mid Pl, 12mB 
 22.98 38.3 Multiparous D D 2.54 low 49.97 1.14 high Pl, CB, 12mB, 12mH 
 38.38 39.7 Multiparous W D 2.56 low 47.37 0.05 mid Pl, CB, 12mB 
 29.65 40.2 Multiparous W D 2.58 low 45.00 0 mid Pl, CB 
 26.92 38.1 Multiparous W D 2.61 low 46.50 0.65 mid Pl, CB, 12mB 
 41.69 38.1 Multiparous D D 2.63 low 48.50 0.9 mid Pl, 12mB 
 40.49 37 Multiparous W W 2.64 low 47.20 1.15 high Pl, CB, 12mB, 12mH 
 19.19 38.1 Primiparous W W 2.67 low 46.50 -4.44 low Pl, CB, 12mB 
 38.56 38.9 Multiparous D W 2.69 low 45.67 1.44 high 12mH 










No copyright is required 
 23.95 39.9 Multiparous W W 2.96 mid 50.27 -0.47 low 12mH 
 22.03 42 Multiparous D D 2.96 mid 49.40 1.67 high 12mH 
 37.22 39.4 Multiparous W D 2.99 mid 49.50 -0.46 low 12mH 
 26.08 38.3 Multiparous D D 3 mid 46.00 -0.46 low 12mH 
 36.2 41.2 Multiparous D D 3.07 mid 50.07 -0.89 low 12mH 
 38.07 40.4 Multiparous D D 3.21 mid 50.27 -0.76 low 12mH 
 34.8 38.9 Multiparous W D 3.25 high 53.20 1.1 high CB 
 35.4 40.4 Multiparous D D 3.29 high 50.50 0.78 mid CB 
 36.78 40.2 Multiparous D W 3.31 high 49.00 0.07 mid Pl 
 32.43 39.7 Multiparous W D 3.33 high 51.00 0.81 mid Pl, CB 
 24.1 39.9 Multiparous W D 3.33 high 50.20 0 mid CB 
 34.3 39.4 Multiparous W D 3.33 high 50.00 -0.67 low CB 
 34.25 41 Multiparous W D 3.37 high 45.17 -1.39 low Pl, CB, 12mB, 12mH 
 39.54 40.2 Multiparous W D 3.42 high 49.80 -1.11 low 12mB, 12mH 
 27.27 39.9 Multiparous D D 3.75 high 53.00 -0.17 mid Pl, CB 
 38.38 40.7 Multiparous D D 3.84 high 47.50 0.97 high Pl, CB, 12mB 
 27.12 41 Multiparous D D 3.97 high 52.00 -0.87 low Pl, 12mB, 12mH 
 27.07  Multiparous D W    1.1 high 12mH 
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Placenta DNA extraction 
     Low BW High BW Total 
     Male 10 14 24 
     Female 11 6 17 
     Both 21 20 41 
                 
  Cordbloods DNA extraction       
    Low BW High BW Total   
 
  
  Male 8 12 20   
 
  
  Female 8 8 16   
 
  
  Both 16 20 36   
 
  
               
  Infant blood (12m) DNA extraction 
    Low BW High BW Total Low LAZ High LAZ Total 
  Male 12 13 25 11 13 24 
  Female 11 4 15 9 7 16 
  Both 23 17 40 20 20 40 
                
  Subjects in Common    
Placenta BW and cord blood BW 30   
Cordblood BW and Infant blood (12m) BW 26   
Cordblood BW and Infant blood (12m) LAZ 11   





















Total Number of 
DMRs 
Direction of Median 
Methylation Change 
for DMRs Relative 
to High Groupings 
for Birthweight and 
LAZ 
+ve                -ve 
Total Number of 
CpG sites in DMRs 
and implicated 
genes 
Placenta BW 4  2                    2 4 (4) 
Cord blood BW 68 25                 43 88 (78) 
Infant blood (12m) 
BW 54 
29                 25 
71 (65) 
Infant blood (12m) 
LAZ 25 
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Genomic Feature Number of CpGs 
in Feature 
Number of CpGs 
in Feature 
% of Total 







Promoter 30 44 37.9 
Promoter and CTCF binding 
site 
9 3 6.2 
CTCF binding site 11 3 7.2 
Transcription Factor binding 
site 
4 1 2.5 
Enhancer 0 1 0.5 
Exon 16 5 10.8 
Intron 28 9 19.5 
Intergenic 17 13 15.4 
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Table 5    
 
                                                            ZFHX3 (% methylation)  
                         Pyrosequencing                                                      Methylseq  
            Sample  High          Sample Low                       Sample  High          Sample Low 
               1             20              1           31                           1              22              1             40 
               2             22              2           31                           2              22              2             42 
               3             23              3           31                           3              23              3              42 
               4             23              4           33                           4              23              4              41 
               5             30              5           35                           5              24              5              40 
                                                 6          35                                                               6             46 
Mean:  23.6  sd+/-3.38       32.6  sd+/-1.79                 22.8  sd+/- 0.74        41.3  sd+/- 1.1 
Individual samples sourced from the 12 month high and low LAZ (length for age) comparison 
groups 
Median methylseq determined methylation change between groups =  -14.8 referenced to high 
LAZ value 













 Developmental Process (GO:0032502) 
A. Panther  GO-Slim Molecular Function 
Binding (GO:0005488) 
Catalytic Activity (GO:0003824) 
Molecular Function Regulator (GO:0098772) 
Molecular Transducer Activity (GO:0060089) 
Transcription Regulator Activity (GO:00140110) 
Translation Regulator Activity (GO:0045182) 
Transporter Activity (GO:0005215) 
B. Panther  GO-Slim Biological Process 
 Metabolic Process (GO:0008152) 
Locomotion (GO:0040011) 
 Localization (GO:0051179) 
 Immune System (GO:0002376) 
Growth (GO:0040007) 
Cellular Process (GO:0009987) 
 Cellular Component Organisation 
  or Biogenesis(GO:0071840) 
 Cell Population Proliferation 
 (GO:0008283) 
 Biological Regulation (GO:0065007) 
 Biological Adhesion (GO:0022610) 
Signalling (GO:0023052) 
Response to Stimulus (GO:0050896) 
Multicellular Organismal Process  
 (GO:0032501) 






























D. Panther  GO-Slim Cellular Component 
 Supramolecular Complex  
 (GO:0099080) 
 Cell Part (GO:0044464) 
 Membrane (GO:0016020) 
 Cell (GO:0005623) 
 Synapse (GO:0045202) 
 Organelle Part (GO:0044422) 
 Membrane-enclosed Lumen  
 (GO:0031974) 
 Protein-containing Complex  
 (GO:0065007) 
 Organelle (GO:0043226) 
 Synapse Part (GO:0044456) 
 Extracellular Region  
 (GO:0005576) 
 Extracellular Region Part  
 (GO:004421) 
 Membrane Part (GO:0044425) 
C. Panther  GO-Slim Protein Class 
 Cell Junction Protein (PC00070) 
 Chromatin/Chromatin-Binding or 
  Regulatory Protein (PC00077) 
 Cytoskeletal Protein (PC00085) 
 Extracellular Matrix (PC00102) 
 Gene-specific Transcriptional Regulator (PC00264) 
 Intracellular Signal Protein (PC00207) 
 Membrane Traffic Protein (PC00150) 
 Metabolite Interconversion Enzyme (PC00262) 
 Nucleic Acid Binding Protein (PC00171) 
 Protein Modifying Enzyme (PC00260) 
 Protein-binding Activity Modulator (PC00095) 
 Scaffold Adapter Protein (PC00226) 
 Transmembrane Signal Receptor (PC00197) 












Implicated Gene Name 





Change  and  p-
value 
Disease Associations from GAWAS Studies Entrez Summary; Phenotype from Functional Studies and 
Mutation Analysis 
BiSeq Analysis >5% 
Methylation Change 
    
Trophoblast     
AL109910.1: Long intergenic 
noncoding RNA  







IKBKB: inhibitor of kappa 
light polypeptide gene 
enhancer in B-cells, kinase 
beta* 
CpG within intron of gene 






Arthritis, Rheumatoid |,Arthritis, Rheumatoid |Rheumatoid 
Arthritis| Anti-TNF Response, Asthma| Bronchiolitis, Viral| 
Respiratory Syncytial Virus Infections, benzene haematotoxicity 
,Bone Mineral Density, Bronchiolitis, Viral| Respiratory Syncytial 
Virus Infections, Colorectal Cancer, diabetes, type 2,Hepatitis C| 
Remission, Spontaneous, HIV, Hodgkin Disease| Leukemia, 
Lymphocytic, Chronic, B-Cell| Lymphoproliferative Disorders| 
Waldenstrom Macroglobulinemia, Lymphoma, Non-Hodgkin, 
multiple myeloma, respiratory syncytial virus bronchiolitis, hyroid 
cancer 
The protein encoded by this gene phosphorylates the inhibitor in the 
inhibitor/NF-kappa-B complex, causing dissociation of the inhibitor and 
activation of NF-kappa-B. The encoded protein itself is found in a 
complex of proteins. Mutations in this gene have been found in 
Immunodeficiency 15A (IMD15A) and 15B (IMD15B). See OMIM 
entries 603258, 618204, 615592 
Cord Blood Birth Weight     
LGR6: Leucine rich repeat 
containing G protein-coupled 
receptor* 
CpG within 3’ exon of gene 








Erythrocyte Count This gene encodes a member of the leucine-rich repeat-containing 
subgroup of the G protein-coupled 7-transmembrane protein 
superfamily. The encoded protein is a glycoprotein hormone receptor 
with a large N-terminal extracellular domain that contains leucine-rich 
repeats important for the formation of a horseshoe-shaped interaction 
motif for ligand binding. 
CRACD: Cancer-Related 
Regulator of Actin Dynamics 
CpG within intron of gene  





Erythrocyte Count, Prostatic Neoplasms, Respiratory Function 
Tests 
Cytoskeletal regulator that stabilizes cadherin-catenin-actin complex. 
Mutated in colorectal cancer. See OMIM entry 618327 
SEMA3B: Semaphorin 3B*  










Lung cancer prostate cancer, Schizophrenia Belongs to the class-3 semaphorin/collapsin family, whose members 
function in growth cone guidance during neuronal development. This 
family member inhibits axonal extension and has been shown to act as 
a tumor suppressor by inducing apoptosis. See OMIM entry 601281 
PHYKPL: 5-phosphohydroxy-
L-lysine phospho-lyase 
CpG within exon of gene 





Acquired Immunodeficiency Syndrome| Disease Progression This is a nuclear gene encoding a mitochondrial enzyme that catalyzes 
the conversion of 5-phosphonooxy-L-lysine to ammonia, inorganic 
phosphate, and 2-aminoadipate semialdehyde. Mutations in this gene 














ANKS1A:  ankyrin repeat and 
sterile alpha motif domain 
containing 1A* 
CpGs within last exon of gene 
198.866, 198.869 downstream 






Alcoholism, Coronary Artery Disease, height,  Lupus 
Erythematosus, Systemic| Systemic lupus erythematosus, 
Tobacco Use Disorder, Type 2 Diabetes| edema | rosiglitazone 
May have a negative role in growth factor receptor signalling pathways. 
See OMIM entry 608994 
TNXB:  tenascin XB* 
CpG intergenic 35.762 kb 










Abortion, Spontaneous, Alzheimer's disease, Arthritis, 
Rheumatoid |,Chronic renal failure |Kidney Failure, Chronic, 
Diabetes Mellitus, Type 1|,diabetes, type 1 ,Ehlers-Danlos 
syndrome,height,HIV-1 control, Lupus Erythematosus, 
Systemic, nasal polyposis, Schizophrenia, smoking behavior, 
Type 2 Diabetes| edema | rosiglitazone 
Member of the tenascin family of extracellular matrix glycoproteins. The 
tenascins have anti-adhesive effects, as opposed to fibronectin which is 
adhesive. This protein is thought to function in matrix maturation during 
wound healing. Mutations give rise to Ehlers-Danlos Syndrome (64) 
and a form of chronic kidney failure, Vesicoureteral Reflux –VUR (65), 
both of which involve alterations to the ECM related to collagen 
deposition. See OMIM entries 600985, 606408, 615963 
AL078602.1: LncRNA 
CpG within intron of transcript 
163.270 kb downstream of TSS 






     
C7orf50: Chromosome 7 
open reading frame 50* 










Longevity Associated with Longevity. 
MAD1L1: MAD1 mitotic arrest 
deficient like 1* 
CpG in last intron of gene 









Bipolar Disorder, Carcinoma, Hepatocellular| Liver Neoplasms| 
Neoplasm Recurrence, Local, Chronic renal failure| Kidney 
Failure, Chronic, Iron, longevity, Lung Cancer, Mental Disorders, 
Myocardial Infarction, Narcolepsy, Neutrophils, Schizophrenia, 
Tobacco Use Disorder 
MAD1L1 is a component of the mitotic spindle-assembly checkpoint 
that prevents the onset of anaphase until all chromosome are properly 
aligned at the metaphase plate. MAD1L1 functions as a homodimer 
and interacts with MAD2L1. MAD1L1 may play a role in cell cycle 
control and tumor suppression. See OMIM entry 602686 
LMTK2: Lemur tyrosine 
kinase 2 
CpG in CpG island 311 base 









Body Fat Distribution, Body Weights and Measures, Chronic 
renal failure| Kidney Failure, Chronic, Echocardiography, null, 
prostate  cancer, Prostatic Neoplasms 
Belongs to the protein tyrosine kinase family and interacts with several 
other proteins, such as Inhibitor-2 (Inh2), protein phosphatase-1 
(PP1C), p35, and myosin VI. It phosporylates other proteins, and is 
itself also phosporylated when interacting with cyclin-dependent kinase 
5 (cdk5)/p35 complex. This protein is involved in nerve growth factor 
(NGF)-TrkA signalling, and also plays a critical role in endosomal 
membrane trafficking. Mouse studies suggested an essential role of this 
protein in spermatogenesis. See OMIM entry 610989 


















CpGs in CpG island 32.8 and 
32.817 kb downstream of TSS 





ZNF395: Zinc finger protein 
395* 
CpG within intron of gene 
49.401 kb downstream of TSS 




 8p21.1: Binding factor for the papilloma virus promoter and the 
Huntington gene promoter. See OMIM entry 606494 
NACC2: NACC family 
member 2* 
CpG 5’ 96 bp upstream from 









Body Fat Distribution, Insulin, Stroke, Tobacco Use Disorder Acts as a transcriptional repressor, has histone deacetylase activity and 
coprecipitates with subunits of the nucleosome remodelling and 
deacetylase (NURD) complex. See OMIM entry 615786 
XPNPEP1: X-prolyl 
aminopeptidase 1* 
CpG within intron of gene 








Alzheimer's disease, biliary atresia, Tobacco Use Disorder Cytosolic form of a metalloaminopeptidase that catalyzes the cleavage 
of the N-terminal amino acid adjacent to a proline residue and may play 
a role in degradation and maturation of tachykinins, neuropeptides, and 
peptide hormones. See OMIM entry 602443 
OR52I1: Olfactory receptor 
family 52  
subfamily I member 1 
CpG within exon 600 bp 
downstream of TSS 




NI The olfactory receptor proteins are members of a large family of G-
protein-coupled receptors (GPCR) arising from single coding-exon 
genes. Olfactory receptors share a 7-transmembrane domain structure 
with many neurotransmitter and hormone receptors and are responsible 
for the recognition and G protein-mediated transduction of odorant 
signals. 
EPS8L2: EPS8 like 2* 
CpG in intron 4.532 kb 






protein 80  
CpG in intron 3.542 kb 







EPS8L2 :Body Weight,Inflammatory Bowel Diseases EPS8L2 protein, like other members of the family, is thought to link 
growth factor stimulation to actin organization, generating functional 
redundancy in the pathways that regulate actin cytoskeletal 
remodelling. Mutations in humans (DFNB106 –Deafness, autosomal 
recessive) and a mouse knock-out model lead to hearing loss. See 
















CpG in CpG island within exon 






NI B4GALNT4 modifies N- or O-linked oligosaccharide structures by 
transferring beta-1,4-linked GalNAc to the terminal acceptors. It is most 
highly expressed in ovary, followed by fetal brain and various adult 
brain regions. B4GALNT4 is also highly expressed in foetal kidney and 
lung. See OMIM entry 618560 
AL512484.1: LncRNA 
CpG intergenic142.139 kb 







ribosylhydrolase like 1* 
CpG within last exon of gene 








NI ADP-ribosyltransferases (see ART1; OMIM 601625) transfer ADP-
ribose from NAD+ to the target protein, and ADP-ribosylhydrolases, 
such as ADPRHL1, reverse the reaction. 
RASA3: RAS p21 protein 
activator 3* 
CpG within intron of gene 









NI Negative regulator of the RAS signalling pathway. 
SERPINA4: Serpin family A 
member 4 
CpG within intron of gene 8.289 
kb downstream of TSS 




 Inhibitors of serine proteases and play and play a role in haemostasis 
and thrombosis. See OMIM entry 147935 
AL355102.2: novel protein 
CpG within intron  47.695 kb 
downstream of TSS 
 
14: position 96252539 -7 
P=1.66E-6 
NI  
DLK1: Delta like non-
canonical Notch ligand* 
CpG within 3’UTR 11.855 kb 





Bone Mineral Density, diabetes, type 1 ,Disease Models, 
Animal| Obesity, null,Optic Disk, type 1 diabetes 
This gene encodes a transmembrane protein that contains multiple 
epidermal growth factor repeats that functions as a regulator of cell 
growth. The encoded protein is involved in the differentiation of several 
cell types including adipocytes. This gene is located in a region of 
chromosome 14 frequently showing uniparental disomy, and is 
imprinted and expressed from the paternal allele. This imprinted region 
is important for growth and development and leads to Temple 
Syndrome when uniparental disomy is present. A single nucleotide 
variant in this gene is associated with child and adolescent obesity and 
shows polar overdominance, where heterozygotes carrying an active 












normal. See OMIM entry 176290 
GABRG3: gamma-
aminobutyric acid type A 
receptor gamma3 subunit 
CpGs within intron of gene 
527.896, 527.887 kb 
downstream of TSS 






alcohol consumption, alcohol dependence, autism, Bipolar 
Disorder, bipolar schizoaffective disorder, Blood Pressure 
Determination, Bulimia, Cholesterol, LDL, Dyskinesia, Drug-
Induced|,Interleukin-6,null,Parkinson Disease, Psychiatric 
Disorders, schizophrenia | autism, several psychiatric disorders, 
Tobacco Use Disorder 
GABA is the major inhibitory neurotransmitter in the mammalian brain 
where it acts at GABA-A receptors, which are ligand-gated chloride 
channels. Chloride conductance of these channels can be modulated 
by agents such as benzodiazepines that bind to the GABA-A receptor. 
GABA-A receptors are pentameric, consisting of proteins from several 
subunit classes: alpha, beta, gamma, delta and rho. The protein 
encoded by this gene is a gamma subunit, which contains the 
benzodiazepine binding site. 
MARVELD3: MARVEL 
domain containing 3 
CpGs  in intron 14.366 kb 
downstream of TSS 





NI Protein found colocalised with occludin at junctional complexes. 
Possible association with resistance to malaria. See OMIM entries 
6140494, 611162. 
MBTPS1: Membrane bound 
transcription factor 
peptidase, site 1 
CpG within intron 57.788 kb 





plasma HDL cholesterol (HDL-C) levels, Type 2 Diabetes| 
edema | rosiglitazone 
This gene encodes a type 1 membrane bound protease which is 
ubiquitously expressed and regulates cholesterol or lipid homeostasis 
via cleavage of substrates at non-basic residues. Mutations in this gene 
may be associated with lysosomal dysfunction. See OMIM entries 
603355, 618392 
PLIN4: Perilipin 4 
CpG within 3’UTR of gene 





Obesity 19p13.3: Coats intracellular lipid storage droplets. Associated with 
obesity. 
NFIX: Nuclear factor I X* 
CpG within intron of gene 
92.356 kb downstream of TSS 
 
Cis-eQTM 




NI The protein encoded by this gene is a transcription factor that binds the 
palindromic sequence 5-TTGGCNNNNNGCCAA-3 in viral and cellular 
promoters. The encoded protein can also stimulate adenovirus 
replication in vitro. Mutations in this gene have been found in Sotos 
Syndrome 2 and Marshall-Smith Syndrome, both associated with over-
growth, skeletal malformation and impaired neural function. See OMIM 
entries 164005, 614753, 602535  
NANOS2: Nanos C2HC-type 
zinc finger 
CpG within exon of gene 204 
bp downstream of TSS 




NI Zinc finger protein expressed in testis. Inactivation of the genes in 
mouse model causes ablation of germ line and infertility. (66) See 
OMIM entry 608228 
BCOR:  BCL6 corepressor  
CpG in  CpG island in first 






NI Interacting corepressor of BCL6, a POZ/zinc finger transcription 
repressor that is required for germinal center formation and may 
influence apoptosis. This protein selectively interacts with the POZ 
domain of BCL6, but not with eight other POZ proteins. Specific class I 
and II histone deacetylases (HDACs) have been shown to interact with 
this protein, which suggests a possible link between the two classes of 
HDACs. Mutations in this gene have been shown to cause 
developmental syndromic microphthalmia-2 (MCOPS2) and 
















PYGO2: Pygopus family PHD 
finger 2* 
CpG in 3’ UTR of gene 5.964 
kb downstream of TSS 




NI The gene product is required for WNT signal transduction at the level of 
nuclear beta-catenin in Drosophila. It is suggested that the recruitment 
of human PYGO permits beta-catenin to transcriptionally activate WNT 
target genes and that deregulation of this interaction may play a causal 
role in the development of B-cell malignancies. See OMIM entry 
606903 
CFAP74:  Cilia and flagella 
associated protein 74 
CpG within intron 18.37, 18.360 







NI Cilia and flagella associated protein with biased expression in the testis. 
KLHL23: Kelch like family 
member 23 
CpG within intron of gene 
21.502 kb downstream of TSS 





CPLX1: Complexin 1*  
CpG intergenic 41.512 kb 





Alcoholism, Behcet Syndrome, Schizophrenia 4p16.3: Cytosolic protein that functions in synaptic vesicle exocytosis. 
Binds to the SNAP receptor complex and disrupts it, allowing 
transmitter release.. Mutations cause Early Infantile Epileptic 
Encephalopathy – EIEE63. See OMIM entry 605032 (67, 68) 
TNXB: Tenascin XB*  
All three CpGs are located 
within intron of  the gene 7.159,  














Abortion, Spontaneous, Alzheimer's disease, Arthritis, 
Rheumatoid |,Chronic renal failure |Kidney Failure, Chronic, 
Diabetes Mellitus, Type 1|,diabetes, type 1 ,Ehlers-Danlos 
syndrome,height,HIV-1 control, Lupus Erythematosus, 
Systemic, nasal polyposis, Schizophrenia, smoking behavior, 
Type 2 Diabetes| edema | rosiglitazone 
Member of the tenascin family of extracellular matrix glycoproteins. The 
tenascins have anti-adhesive effects, as opposed to fibronectin which is 
adhesive. This protein is thought to function in matrix maturation during 
wound healing. Mutations give rise to Ehlers-Danlos Syndrome (64) 
and a form of chronic kidney failure, Vesicoureteral Reflux –VUR (65), 
both of which involve alterations to the ECM related to collagen 
deposition. See OMIM entries 600985, 606408, 615963 
DMTN: Dematin actin binding 
protein* 
CpG within first intron of gene 





NI The protein encoded by this gene is an actin binding and bundling 
protein that plays a structural role in erythrocytes, by stabilizing and 
attaching the spectrin/actin cytoskeleton to the erythrocyte membrane 
in a phosphorylation-dependent manner. Disruption of this gene in a 
mouse model causes severe instability of the erythrocyte membrane 
and hypermethylation metastasis of colorectal cancer (69)  
AC016816.1: novel transcript 
LncRNA 
CpG intergenic 306.103 kb  
downstream of TSS and 








     
MEG9:  maternally expressed  
9 (LINC00584)* 
CpG within last exon of gene 
4.468 kb downstream of TSS 
14Q32: position 
101072751 
+22.6 Body mass and age of menarche (ref) 14q32: Maternally expressed imprinted non-coding RNA (LINC00584). 
Functional studies indicate role in megakaryocyte differentiation and 













     
KIF26A:  Kinesin family 
member 26A* 
CpGs intergenic 32.529 and 
32.545 kb 3’ to gene 





Pancreatic Neoplasms, Stroke, Waist Circumference Microtubule associated kinesin. Mouse KO model shows growth 
retardation with defective development of the bowel. See OMIM entry 
613231 
SGTA: Small glutamine rich 
tetratricopeptide repeat 
containing alpha 
CpG within intron of gene 








Insulin Resistance |Polycystic Ovary Syndrome, POLYCYSTIC 
OVARIAN SYNDROME |Polycystic Ovary Syndrome 
SGTA protein interacts with the growth hormone (69) and steroid 
hormone (both androgen and progesterone) receptor signalling 
pathways (72, 73), potentially regulating growth and development of 
polycystic ovary syndrome, prostate and breast cancers (73). SGTA 
also promotes the proteasomal degradation of mislocalized proteins 
and protects Amyloid Precursor Protein from such a fate, possibly 
implicating it in Alzheimer’s Disease (73) 
MYT1: myelin transcription 
factor 1.  
CpG in CpG island within first 
intron of gene 31.563 kb 





NI The protein encoded by this gene is a member of a family of neural 
specific, zinc finger-containing DNA-binding proteins. The protein binds 
to the promoter regions of proteolipid proteins of the central nervous 
system and plays a role in the developing nervous system. Inactivation 
of the gene in a mouse model is embryonic lethal with poor innervation 
of the diaphragm. Conditional pancreatic inactivation is associated with 
a glucose intolerance phenotype. Mutation of MYT1 has been found in 
a patient with Hemifacial macrosomia (HFM). See OMIM entries 
600379, 164210 
TAB1: TGF-beta activated 
kinase 1 (MAP3K7) binding 
protein 1* 
CpGs in CpG island 
10.653.10.646, 10.642, 10.636 












Arthritis, Rheumatoid |Rheumatoid Arthritis, Arthritis, 
Rheumatoid| Rheumatoid Arthritis| Anti-TNF Response, Crohn 
Disease| Crohn's disease 
This gene was identified as a regulator of the MAP kinase kinase 
kinase MAP3K7/TAK1, which is known to mediate various intracellular 
signaling pathways, such as those induced by TGF beta, interleukin 1, 
and WNT-1. This protein interacts and thus activates TAK1 kinase. It 
has been shown that the C-terminal portion of this protein is sufficient 
for binding and activation of TAK1, while a portion of the N-terminus 
acts as a dominant-negative inhibitor of TGF beta, suggesting that this 
protein may function as a mediator between TGF beta receptors and 
TAK1. This protein can also interact with and activate the mitogen-
activated protein kinase 14 (MAPK14/p38alpha), and thus represents 
an alternative activation pathway, in addition to the MAPKK pathways, 
which contributes to the biological responses of MAPK14 to various 
stimuli. See OMIM entry 602615 
     
Infant Blood LAZ     
HLX: H2.0 like homeobox* 
 
CpG intergenic 10.8 kb 5’ to 
gene 




Aorta, Asthma, Asthma|, Blood Pressure, Body Height, 
Cholesterol, Cholesterol, LDL, Dupuytren Contracture, 
Echocardiography, Hip, Leukemia, Myeloid, Mortality 
Over expression and insertional ablation in transgenic mice indicate a 
role in CD4+ T lymphocyte development (74) and liver and gut 
organogenesis (75) respectively. It is interesting to note that the gene 
has also been found to be expressed in cytotrophoblast cell types in 
early pregnancy human placentas (76), to be a regulator of trophoblast 
proliferation (77) and shows reduced expression associated with foetal 















homolog (yeast)  
pseudogene 






IRF4: Interferon regulatory 
factor 4 










Abortion, Spontaneous, benzene haematotoxicity, Black vs 
blond hair color, Black vs red hair color, Carcinoma, Basal Cell, 
Celiac disease Chromosome Aberrations| Chromosome 
abnormality| Chronic Lymphocytic Leukemia Leukemia, 
Lymphocytic, Chronic, B-Cell,Chromosome  Aberrations| 
Chromosome abnormality |Lymphocytosis, Chronic lymphocytic 
leukemia, Chronic Lymphocytic Leukemia |Hodgkin Disease 
|Leukemia, Lymphocytic, Chronic, B-Cell| Multiple Myeloma, 
Chronic Lymphocytic Leukemia| Leukemia, Lymphocytic, 
Chronic, B-Cell, Chronic Lymphocytic Leukemia| Leukemia, 
Lymphocytic, Chronic, B-Cell |Lymphoma| Syndrome, Chronic 
renal failure| Kidney Failure, Chronic, Eye Color, freckles, Hair 
Color, HIV, Hodgkin Disease |Leukemia, Lymphocytic, Chronic, 
B-Cell| Lymphoproliferative Disorders| Waldenstrom 
Macroglobulinemia, leukemia, Leukemia, Lymphocytic, Chronic, 
B-Cell ,Leukemia, Lymphoid, lymphoma,melanoma ,melanoma| 
Nevus| Skin Neoplasms, melanoma| Nevus| Skin Neoplasms| 
Sunburn, Melanosis, multiple myeloma ,Multiple Sclerosis, 
Neuroblastoma, Skin Neoplasms, Suntan, Supranuclear Palsy, 
Progressive, tanning phenotype 
Belongs to the IRF (interferon regulatory factor) family of transcription 
factors, characterized by an unique tryptophan pentad repeat DNA-
binding domain. The IRFs are important in the regulation of interferons 
in response to infection by virus, and in the regulation of interferon-
inducible genes. This family member is lymphocyte specific and 
negatively regulates Toll-like-receptor (TLR) signaling that is central to 
the activation of innate and adaptive immune systems. A chromosomal 
translocation involving this gene and the IgH locus, t(6;14)(p25;q32), 
may be a cause of multiple myeloma. See OMIM entries 601900, 
612558 
ZFHX3:  Zinc finger* 
homeobox 3 
CpG within intron of gene 





Alcoholism, Atrial  Fibrillation, Atrial Fibrillation| Atrial Fibrillation| 
Brain Ischemia| Stroke, Body Mass Index, Cardiovascular 
Diseases, Coronary Disease, Kawasaki disease 
,Mucocutaneous Lymph Node Syndrome, Myocardial Infarction| 
Ventricular Fibrillation, prostate cancer, Tobacco Use Disorder, 
Waist Circumference 
ZFHX3 (a zinc finger homeobox transcription factor - also known as 
ATFB1, Atrial fibrillation, family 1) can both repress and activate genes 
in cooperation with TGF beta signalling (79, 80, 81). Genetic evidence 
implicates the gene in a number of disease phenotypes; breast cancer 
through mutation and interaction with the oestrogen receptor (82, 83), 
gastric cancer (80) and prostate cancer (82). The important role the 
gene plays in myogenic differentiation (83) correlates with the genetic 
association to atrial fibrillation and other cardiac phenotypes. See 
OMIM entries 104155, 613055 
LINC00511: long intergenic 
non-protein coding RNA 511. 
CpG in intron of gene 260.980 
kb downstream of TSS 




NI Long intergenic non-coding RNA involved in promoting several cancers 
through regulation of a variety of microRNAs. Acts as an oncogenic 
LINCRNA (84) 












 Implicated Gene Name 





Change  and  p-
value 
Disease Associations from GAWAS Studies Entrez Summary; Phenotype from Functional Studies and 
Mutation Analysis 
BiSeq Analysis >5% 
Methylation Change 
    
Trophoblast     
AL109910.1: Long intergenic 
noncoding RNA  







IKBKB: inhibitor of kappa 
light polypeptide gene 
enhancer in B-cells, kinase 
beta* 
CpG within intron of gene 






Arthritis, Rheumatoid |,Arthritis, Rheumatoid |Rheumatoid 
Arthritis| Anti-TNF Response, Asthma| Bronchiolitis, Viral| 
Respiratory Syncytial Virus Infections, benzene haematotoxicity 
,Bone Mineral Density, Bronchiolitis, Viral| Respiratory Syncytial 
Virus Infections, Colorectal Cancer, diabetes, type 2,Hepatitis C| 
Remission, Spontaneous, HIV, Hodgkin Disease| Leukemia, 
Lymphocytic, Chronic, B-Cell| Lymphoproliferative Disorders| 
Waldenstrom Macroglobulinemia, Lymphoma, Non-Hodgkin, 
multiple myeloma, respiratory syncytial virus bronchiolitis, hyroid 
cancer 
The protein encoded by this gene phosphorylates the inhibitor in the 
inhibitor/NF-kappa-B complex, causing dissociation of the inhibitor and 
activation of NF-kappa-B. The encoded protein itself is found in a 
complex of proteins. Mutations in this gene have been found in 
Immunodeficiency 15A (IMD15A) and 15B (IMD15B). See OMIM 
entries 603258, 618204, 615592 
Cord Blood Birth Weight     
LGR6: Leucine rich repeat 
containing G protein-coupled 
receptor* 
CpG within 3’ exon of gene 








Erythrocyte Count This gene encodes a member of the leucine-rich repeat-containing 
subgroup of the G protein-coupled 7-transmembrane protein 
superfamily. The encoded protein is a glycoprotein hormone receptor 
with a large N-terminal extracellular domain that contains leucine-rich 
repeats important for the formation of a horseshoe-shaped interaction 
motif for ligand binding. 
CRACD: Cancer-Related 
Regulator of Actin Dynamics 
CpG within intron of gene  





Erythrocyte Count, Prostatic Neoplasms, Respiratory Function 
Tests 
Cytoskeletal regulator that stabilizes cadherin-catenin-actin complex. 
Mutated in colorectal cancer. See OMIM entry 618327 
SEMA3B: Semaphorin 3B*  










Lung cancer prostate cancer, Schizophrenia Belongs to the class-3 semaphorin/collapsin family, whose members 
function in growth cone guidance during neuronal development. This 
family member inhibits axonal extension and has been shown to act as 
a tumor suppressor by inducing apoptosis. See OMIM entry 601281 
PHYKPL: 5-phosphohydroxy-
L-lysine phospho-lyase 
CpG within exon of gene 





Acquired Immunodeficiency Syndrome| Disease Progression This is a nuclear gene encoding a mitochondrial enzyme that catalyzes 
the conversion of 5-phosphonooxy-L-lysine to ammonia, inorganic 
phosphate, and 2-aminoadipate semialdehyde. Mutations in this gene 















ANKS1A:  ankyrin repeat and 
sterile alpha motif domain 
containing 1A* 
CpGs within last exon of gene 
198.866, 198.869 downstream 






Alcoholism, Coronary Artery Disease, height,  Lupus 
Erythematosus, Systemic| Systemic lupus erythematosus, 
Tobacco Use Disorder, Type 2 Diabetes| edema | rosiglitazone 
May have a negative role in growth factor receptor signalling pathways. 
See OMIM entry 608994 
TNXB:  tenascin XB* 
CpG intergenic 35.762 kb 










Abortion, Spontaneous, Alzheimer's disease, Arthritis, 
Rheumatoid |,Chronic renal failure |Kidney Failure, Chronic, 
Diabetes Mellitus, Type 1|,diabetes, type 1 ,Ehlers-Danlos 
syndrome,height,HIV-1 control, Lupus Erythematosus, 
Systemic, nasal polyposis, Schizophrenia, smoking behavior, 
Type 2 Diabetes| edema | rosiglitazone 
Member of the tenascin family of extracellular matrix glycoproteins. The 
tenascins have anti-adhesive effects, as opposed to fibronectin which is 
adhesive. This protein is thought to function in matrix maturation during 
wound healing. Mutations give rise to Ehlers-Danlos Syndrome (64) 
and a form of chronic kidney failure, Vesicoureteral Reflux –VUR (65), 
both of which involve alterations to the ECM related to collagen 
deposition. See OMIM entries 600985, 606408, 615963 
AL078602.1: LncRNA 
CpG within intron of transcript 
163.270 kb downstream of TSS 






     
C7orf50: Chromosome 7 
open reading frame 50* 










Longevity Associated with Longevity. 
MAD1L1: MAD1 mitotic arrest 
deficient like 1* 
CpG in last intron of gene 









Bipolar Disorder, Carcinoma, Hepatocellular| Liver Neoplasms| 
Neoplasm Recurrence, Local, Chronic renal failure| Kidney 
Failure, Chronic, Iron, longevity, Lung Cancer, Mental Disorders, 
Myocardial Infarction, Narcolepsy, Neutrophils, Schizophrenia, 
Tobacco Use Disorder 
MAD1L1 is a component of the mitotic spindle-assembly checkpoint 
that prevents the onset of anaphase until all chromosome are properly 
aligned at the metaphase plate. MAD1L1 functions as a homodimer 
and interacts with MAD2L1. MAD1L1 may play a role in cell cycle 
control and tumor suppression. See OMIM entry 602686 
LMTK2: Lemur tyrosine 
kinase 2 
CpG in CpG island 311 base 









Body Fat Distribution, Body Weights and Measures, Chronic 
renal failure| Kidney Failure, Chronic, Echocardiography, null, 
prostate  cancer, Prostatic Neoplasms 
Belongs to the protein tyrosine kinase family and interacts with several 
other proteins, such as Inhibitor-2 (Inh2), protein phosphatase-1 
(PP1C), p35, and myosin VI. It phosporylates other proteins, and is 
itself also phosporylated when interacting with cyclin-dependent kinase 
5 (cdk5)/p35 complex. This protein is involved in nerve growth factor 
(NGF)-TrkA signalling, and also plays a critical role in endosomal 
membrane trafficking. Mouse studies suggested an essential role of this 
protein in spermatogenesis. See OMIM entry 610989 



















CpGs in CpG island 32.8 and 
32.817 kb downstream of TSS 





ZNF395: Zinc finger protein 
395* 
CpG within intron of gene 
49.401 kb downstream of TSS 




 8p21.1: Binding factor for the papilloma virus promoter and the 
Huntington gene promoter. See OMIM entry 606494 
NACC2: NACC family 
member 2* 
CpG 5’ 96 bp upstream from 









Body Fat Distribution, Insulin, Stroke, Tobacco Use Disorder Acts as a transcriptional repressor, has histone deacetylase activity and 
coprecipitates with subunits of the nucleosome remodelling and 
deacetylase (NURD) complex. See OMIM entry 615786 
XPNPEP1: X-prolyl 
aminopeptidase 1* 
CpG within intron of gene 








Alzheimer's disease, biliary atresia, Tobacco Use Disorder Cytosolic form of a metalloaminopeptidase that catalyzes the cleavage 
of the N-terminal amino acid adjacent to a proline residue and may play 
a role in degradation and maturation of tachykinins, neuropeptides, and 
peptide hormones. See OMIM entry 602443 
OR52I1: Olfactory receptor 
family 52  
subfamily I member 1 
CpG within exon 600 bp 
downstream of TSS 




NI The olfactory receptor proteins are members of a large family of G-
protein-coupled receptors (GPCR) arising from single coding-exon 
genes. Olfactory receptors share a 7-transmembrane domain structure 
with many neurotransmitter and hormone receptors and are responsible 
for the recognition and G protein-mediated transduction of odorant 
signals. 
EPS8L2: EPS8 like 2* 
CpG in intron 4.532 kb 






protein 80  
CpG in intron 3.542 kb 







EPS8L2 :Body Weight,Inflammatory Bowel Diseases EPS8L2 protein, like other members of the family, is thought to link 
growth factor stimulation to actin organization, generating functional 
redundancy in the pathways that regulate actin cytoskeletal 
remodelling. Mutations in humans (DFNB106 –Deafness, autosomal 
recessive) and a mouse knock-out model lead to hearing loss. See 

















CpG in CpG island within exon 






NI B4GALNT4 modifies N- or O-linked oligosaccharide structures by 
transferring beta-1,4-linked GalNAc to the terminal acceptors. It is most 
highly expressed in ovary, followed by fetal brain and various adult 
brain regions. B4GALNT4 is also highly expressed in foetal kidney and 
lung. See OMIM entry 618560 
AL512484.1: LncRNA 
CpG intergenic142.139 kb 







ribosylhydrolase like 1* 
CpG within last exon of gene 








NI ADP-ribosyltransferases (see ART1; OMIM 601625) transfer ADP-
ribose from NAD+ to the target protein, and ADP-ribosylhydrolases, 
such as ADPRHL1, reverse the reaction. 
RASA3: RAS p21 protein 
activator 3* 
CpG within intron of gene 









NI Negative regulator of the RAS signalling pathway. 
SERPINA4: Serpin family A 
member 4 
CpG within intron of gene 8.289 
kb downstream of TSS 




 Inhibitors of serine proteases and play and play a role in haemostasis 
and thrombosis. See OMIM entry 147935 
AL355102.2: novel protein 
CpG within intron  47.695 kb 
downstream of TSS 
 
14: position 96252539 -7 
P=1.66E-6 
NI  
DLK1: Delta like non-
canonical Notch ligand* 
CpG within 3’UTR 11.855 kb 





Bone Mineral Density, diabetes, type 1 ,Disease Models, 
Animal| Obesity, null,Optic Disk, type 1 diabetes 
This gene encodes a transmembrane protein that contains multiple 
epidermal growth factor repeats that functions as a regulator of cell 
growth. The encoded protein is involved in the differentiation of several 
cell types including adipocytes. This gene is located in a region of 
chromosome 14 frequently showing uniparental disomy, and is 
imprinted and expressed from the paternal allele. This imprinted region 
is important for growth and development and leads to Temple 
Syndrome when uniparental disomy is present. A single nucleotide 
variant in this gene is associated with child and adolescent obesity and 
shows polar overdominance, where heterozygotes carrying an active 













normal. See OMIM entry 176290 
GABRG3: gamma-
aminobutyric acid type A 
receptor gamma3 subunit 
CpGs within intron of gene 
527.896, 527.887 kb 
downstream of TSS 






alcohol consumption, alcohol dependence, autism, Bipolar 
Disorder, bipolar schizoaffective disorder, Blood Pressure 
Determination, Bulimia, Cholesterol, LDL, Dyskinesia, Drug-
Induced|,Interleukin-6,null,Parkinson Disease, Psychiatric 
Disorders, schizophrenia | autism, several psychiatric disorders, 
Tobacco Use Disorder 
GABA is the major inhibitory neurotransmitter in the mammalian brain 
where it acts at GABA-A receptors, which are ligand-gated chloride 
channels. Chloride conductance of these channels can be modulated 
by agents such as benzodiazepines that bind to the GABA-A receptor. 
GABA-A receptors are pentameric, consisting of proteins from several 
subunit classes: alpha, beta, gamma, delta and rho. The protein 
encoded by this gene is a gamma subunit, which contains the 
benzodiazepine binding site. 
MARVELD3: MARVEL 
domain containing 3 
CpGs  in intron 14.366 kb 
downstream of TSS 





NI Protein found colocalised with occludin at junctional complexes. 
Possible association with resistance to malaria. See OMIM entries 
6140494, 611162. 
MBTPS1: Membrane bound 
transcription factor 
peptidase, site 1 
CpG within intron 57.788 kb 





plasma HDL cholesterol (HDL-C) levels, Type 2 Diabetes| 
edema | rosiglitazone 
This gene encodes a type 1 membrane bound protease which is 
ubiquitously expressed and regulates cholesterol or lipid homeostasis 
via cleavage of substrates at non-basic residues. Mutations in this gene 
may be associated with lysosomal dysfunction. See OMIM entries 
603355, 618392 
PLIN4: Perilipin 4 
CpG within 3’UTR of gene 





Obesity 19p13.3: Coats intracellular lipid storage droplets. Associated with 
obesity. 
NFIX: Nuclear factor I X* 
CpG within intron of gene 
92.356 kb downstream of TSS 
 
Cis-eQTM 




NI The protein encoded by this gene is a transcription factor that binds the 
palindromic sequence 5-TTGGCNNNNNGCCAA-3 in viral and cellular 
promoters. The encoded protein can also stimulate adenovirus 
replication in vitro. Mutations in this gene have been found in Sotos 
Syndrome 2 and Marshall-Smith Syndrome, both associated with over-
growth, skeletal malformation and impaired neural function. See OMIM 
entries 164005, 614753, 602535  
NANOS2: Nanos C2HC-type 
zinc finger 
CpG within exon of gene 204 
bp downstream of TSS 




NI Zinc finger protein expressed in testis. Inactivation of the genes in 
mouse model causes ablation of germ line and infertility. (66) See 
OMIM entry 608228 
BCOR:  BCL6 corepressor  
CpG in  CpG island in first 






NI Interacting corepressor of BCL6, a POZ/zinc finger transcription 
repressor that is required for germinal center formation and may 
influence apoptosis. This protein selectively interacts with the POZ 
domain of BCL6, but not with eight other POZ proteins. Specific class I 
and II histone deacetylases (HDACs) have been shown to interact with 
this protein, which suggests a possible link between the two classes of 
HDACs. Mutations in this gene have been shown to cause 
developmental syndromic microphthalmia-2 (MCOPS2) and 

















PYGO2: Pygopus family PHD 
finger 2* 
CpG in 3’ UTR of gene 5.964 
kb downstream of TSS 




NI The gene product is required for WNT signal transduction at the level of 
nuclear beta-catenin in Drosophila. It is suggested that the recruitment 
of human PYGO permits beta-catenin to transcriptionally activate WNT 
target genes and that deregulation of this interaction may play a causal 
role in the development of B-cell malignancies. See OMIM entry 
606903 
CFAP74:  Cilia and flagella 
associated protein 74 
CpG within intron 18.37, 18.360 







NI Cilia and flagella associated protein with biased expression in the testis. 
KLHL23: Kelch like family 
member 23 
CpG within intron of gene 
21.502 kb downstream of TSS 





CPLX1: Complexin 1*  
CpG intergenic 41.512 kb 





Alcoholism, Behcet Syndrome, Schizophrenia 4p16.3: Cytosolic protein that functions in synaptic vesicle exocytosis. 
Binds to the SNAP receptor complex and disrupts it, allowing 
transmitter release.. Mutations cause Early Infantile Epileptic 
Encephalopathy – EIEE63. See OMIM entry 605032 (67, 68) 
TNXB: Tenascin XB*  
All three CpGs are located 
within intron of  the gene 7.159,  














Abortion, Spontaneous, Alzheimer's disease, Arthritis, 
Rheumatoid |,Chronic renal failure |Kidney Failure, Chronic, 
Diabetes Mellitus, Type 1|,diabetes, type 1 ,Ehlers-Danlos 
syndrome,height,HIV-1 control, Lupus Erythematosus, 
Systemic, nasal polyposis, Schizophrenia, smoking behavior, 
Type 2 Diabetes| edema | rosiglitazone 
Member of the tenascin family of extracellular matrix glycoproteins. The 
tenascins have anti-adhesive effects, as opposed to fibronectin which is 
adhesive. This protein is thought to function in matrix maturation during 
wound healing. Mutations give rise to Ehlers-Danlos Syndrome (64) 
and a form of chronic kidney failure, Vesicoureteral Reflux –VUR (65), 
both of which involve alterations to the ECM related to collagen 
deposition. See OMIM entries 600985, 606408, 615963 
DMTN: Dematin actin binding 
protein* 
CpG within first intron of gene 





NI The protein encoded by this gene is an actin binding and bundling 
protein that plays a structural role in erythrocytes, by stabilizing and 
attaching the spectrin/actin cytoskeleton to the erythrocyte membrane 
in a phosphorylation-dependent manner. Disruption of this gene in a 
mouse model causes severe instability of the erythrocyte membrane 
and hypermethylation metastasis of colorectal cancer (69)  
AC016816.1: novel transcript 
LncRNA 
CpG intergenic 306.103 kb  
downstream of TSS and 








     
MEG9:  maternally expressed  
9 (LINC00584)* 
CpG within last exon of gene 
4.468 kb downstream of TSS 
14Q32: position 
101072751 
+22.6 Body mass and age of menarche (ref) 14q32: Maternally expressed imprinted non-coding RNA (LINC00584). 
Functional studies indicate role in megakaryocyte differentiation and 














     
KIF26A:  Kinesin family 
member 26A* 
CpGs intergenic 32.529 and 
32.545 kb 3’ to gene 





Pancreatic Neoplasms, Stroke, Waist Circumference Microtubule associated kinesin. Mouse KO model shows growth 
retardation with defective development of the bowel. See OMIM entry 
613231 
SGTA: Small glutamine rich 
tetratricopeptide repeat 
containing alpha 
CpG within intron of gene 








Insulin Resistance |Polycystic Ovary Syndrome, POLYCYSTIC 
OVARIAN SYNDROME |Polycystic Ovary Syndrome 
SGTA protein interacts with the growth hormone (69) and steroid 
hormone (both androgen and progesterone) receptor signalling 
pathways (72, 73), potentially regulating growth and development of 
polycystic ovary syndrome, prostate and breast cancers (73). SGTA 
also promotes the proteasomal degradation of mislocalized proteins 
and protects Amyloid Precursor Protein from such a fate, possibly 
implicating it in Alzheimer’s Disease (73) 
MYT1: myelin transcription 
factor 1.  
CpG in CpG island within first 
intron of gene 31.563 kb 





NI The protein encoded by this gene is a member of a family of neural 
specific, zinc finger-containing DNA-binding proteins. The protein binds 
to the promoter regions of proteolipid proteins of the central nervous 
system and plays a role in the developing nervous system. Inactivation 
of the gene in a mouse model is embryonic lethal with poor innervation 
of the diaphragm. Conditional pancreatic inactivation is associated with 
a glucose intolerance phenotype. Mutation of MYT1 has been found in 
a patient with Hemifacial macrosomia (HFM). See OMIM entries 
600379, 164210 
TAB1: TGF-beta activated 
kinase 1 (MAP3K7) binding 
protein 1* 
CpGs in CpG island 
10.653.10.646, 10.642, 10.636 












Arthritis, Rheumatoid |Rheumatoid Arthritis, Arthritis, 
Rheumatoid| Rheumatoid Arthritis| Anti-TNF Response, Crohn 
Disease| Crohn's disease 
This gene was identified as a regulator of the MAP kinase kinase 
kinase MAP3K7/TAK1, which is known to mediate various intracellular 
signaling pathways, such as those induced by TGF beta, interleukin 1, 
and WNT-1. This protein interacts and thus activates TAK1 kinase. It 
has been shown that the C-terminal portion of this protein is sufficient 
for binding and activation of TAK1, while a portion of the N-terminus 
acts as a dominant-negative inhibitor of TGF beta, suggesting that this 
protein may function as a mediator between TGF beta receptors and 
TAK1. This protein can also interact with and activate the mitogen-
activated protein kinase 14 (MAPK14/p38alpha), and thus represents 
an alternative activation pathway, in addition to the MAPKK pathways, 
which contributes to the biological responses of MAPK14 to various 
stimuli. See OMIM entry 602615 
     
Infant Blood LAZ     
HLX: H2.0 like homeobox* 
 
CpG intergenic 10.8 kb 5’ to 
gene 




Aorta, Asthma, Asthma|, Blood Pressure, Body Height, 
Cholesterol, Cholesterol, LDL, Dupuytren Contracture, 
Echocardiography, Hip, Leukemia, Myeloid, Mortality 
Over expression and insertional ablation in transgenic mice indicate a 
role in CD4+ T lymphocyte development (74) and liver and gut 
organogenesis (75) respectively. It is interesting to note that the gene 
has also been found to be expressed in cytotrophoblast cell types in 
early pregnancy human placentas (76), to be a regulator of trophoblast 
proliferation (77) and shows reduced expression associated with foetal 















homolog (yeast)  
pseudogene 






IRF4: Interferon regulatory 
factor 4 










Abortion, Spontaneous, benzene haematotoxicity, Black vs 
blond hair color, Black vs red hair color, Carcinoma, Basal Cell, 
Celiac disease Chromosome Aberrations| Chromosome 
abnormality| Chronic Lymphocytic Leukemia Leukemia, 
Lymphocytic, Chronic, B-Cell,Chromosome  Aberrations| 
Chromosome abnormality |Lymphocytosis, Chronic lymphocytic 
leukemia, Chronic Lymphocytic Leukemia |Hodgkin Disease 
|Leukemia, Lymphocytic, Chronic, B-Cell| Multiple Myeloma, 
Chronic Lymphocytic Leukemia| Leukemia, Lymphocytic, 
Chronic, B-Cell, Chronic Lymphocytic Leukemia| Leukemia, 
Lymphocytic, Chronic, B-Cell |Lymphoma| Syndrome, Chronic 
renal failure| Kidney Failure, Chronic, Eye Color, freckles, Hair 
Color, HIV, Hodgkin Disease |Leukemia, Lymphocytic, Chronic, 
B-Cell| Lymphoproliferative Disorders| Waldenstrom 
Macroglobulinemia, leukemia, Leukemia, Lymphocytic, Chronic, 
B-Cell ,Leukemia, Lymphoid, lymphoma,melanoma ,melanoma| 
Nevus| Skin Neoplasms, melanoma| Nevus| Skin Neoplasms| 
Sunburn, Melanosis, multiple myeloma ,Multiple Sclerosis, 
Neuroblastoma, Skin Neoplasms, Suntan, Supranuclear Palsy, 
Progressive, tanning phenotype 
Belongs to the IRF (interferon regulatory factor) family of transcription 
factors, characterized by an unique tryptophan pentad repeat DNA-
binding domain. The IRFs are important in the regulation of interferons 
in response to infection by virus, and in the regulation of interferon-
inducible genes. This family member is lymphocyte specific and 
negatively regulates Toll-like-receptor (TLR) signaling that is central to 
the activation of innate and adaptive immune systems. A chromosomal 
translocation involving this gene and the IgH locus, t(6;14)(p25;q32), 
may be a cause of multiple myeloma. See OMIM entries 601900, 
612558 
ZFHX3:  Zinc finger* 
homeobox 3 
CpG within intron of gene 





Alcoholism, Atrial  Fibrillation, Atrial Fibrillation| Atrial Fibrillation| 
Brain Ischemia| Stroke, Body Mass Index, Cardiovascular 
Diseases, Coronary Disease, Kawasaki disease 
,Mucocutaneous Lymph Node Syndrome, Myocardial Infarction| 
Ventricular Fibrillation, prostate cancer, Tobacco Use Disorder, 
Waist Circumference 
ZFHX3 (a zinc finger homeobox transcription factor - also known as 
ATFB1, Atrial fibrillation, family 1) can both repress and activate genes 
in cooperation with TGF beta signalling (79, 80, 81). Genetic evidence 
implicates the gene in a number of disease phenotypes; breast cancer 
through mutation and interaction with the oestrogen receptor (82, 83), 
gastric cancer (80) and prostate cancer (82). The important role the 
gene plays in myogenic differentiation (83) correlates with the genetic 
association to atrial fibrillation and other cardiac phenotypes. See 
OMIM entries 104155, 613055 
LINC00511: long intergenic 
non-protein coding RNA 511. 
CpG in intron of gene 260.980 
kb downstream of TSS 




NI Long intergenic non-coding RNA involved in promoting several cancers 
through regulation of a variety of microRNAs. Acts as an oncogenic 
LINCRNA (84) 
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